Genetische Grundlagen der Kanzerogenese

  • C. R. Bartram


Bevor genetische Aspekte von Tumoren des Menschen besprochen werden, soll zunächst ein Eindruck von der Komplexität des menschlichen Genoms und des von ihm gesteuerten Informationsflusses vermittelt werden (Kulozik et al. 2000).


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aas T, Borresen AL, Geisler S et al. (1996) Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Med 2: 811–814PubMedGoogle Scholar
  2. Adjei AA (2001) Blocking oncogenic Ras signaling for cancer therapy.) Natl Cancer Inst 93: 1062–1074Google Scholar
  3. AgaliotiT,Chen G,Thanos D (2002) Deciphering the transcriptional histone acetylation code for a human gene. Cell 111: 381–392Google Scholar
  4. Agami R, Blandino G,Oren M et al. (1999) Interaction of c-Abl and p73a and their collaboration to induce apoptosis. Nature 399: 809–813PubMedGoogle Scholar
  5. Aguilar F, Hussain SP,Cerutti P (1993) Aflatoxin B1 induces the transversion of G toT in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc Natl Acad Sci USA 90: 8586–8590PubMedGoogle Scholar
  6. Ahmadian MR (2002) Prospects for anti-RAS drugs. Br J Haematol 116: 511–518PubMedGoogle Scholar
  7. Ahmadian MR, ZorT,Vogt D et al. (1999) Guanosine triphosphatase stimulation of oncogenic Ras mutants. Proc Natl Acad Sci USA 96: 7065–7070PubMedGoogle Scholar
  8. Almoguera C, Shibata D, Forrester K et al. (1988) Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53: 549–554PubMedGoogle Scholar
  9. Alsanea O, Clark OH (2001) Familial thyroid cancer. Curr Opin Oncol 13: 44–51PubMedGoogle Scholar
  10. Aman P (1999) Fusion genes in solid tumors. Cancer Biol 9: 303–318Google Scholar
  11. Amiel J, Lyonnet S (2001) Hirschsprung disease,associated syndromes, and genetics: a review.J Med Genet 38: 729–739Google Scholar
  12. Amir RE,Van den Veyver IB,Wan M et al. (1999) Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nature Genet 23: 185–188Google Scholar
  13. Ananthaswamy HN, Loughlin SM,Cox Petal. (1997) Sunlight and skin cancer: inhibition of p53 mutations in UV-irradiated mouse skin by sunscreens. Nature Med 3: 510–514Google Scholar
  14. Anderson SF, Schlegel BP, Nakajima T et al. (1998) BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. Nature Genet 19: 254–256PubMedGoogle Scholar
  15. Anker P, Lyautey J, Lederrey C et al. (2001) Circulating nucleic acids in plasma or serum. Clin Chim Acta 313: 143–146PubMedGoogle Scholar
  16. Apperley JF, Gardembras M, Melo JV et al. (2002) Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347: 481–487PubMedGoogle Scholar
  17. Armstrong SA, Staunton JE Silverman LB et al. (2002) MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nature Genet 30: 41–47PubMedGoogle Scholar
  18. Ashkenas J (1997) Gene regulation by mRNA editing. Am J Hum Genet 60: 278–293PubMedGoogle Scholar
  19. Avner P, Heard E (2001) X-chromosome inactivation:counting,choice and initiation. Nature Genet 2: 59–67Google Scholar
  20. Bahram F,von der Lehr N,Cetinkaya C et al. (2000) c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood 95:2104–2110Google Scholar
  21. Bailleul B, Surani MA, White Set al. (1990) Skin hyperkeratosis and papilloma formation in transgenic mice expressing a ras oncogene from a suprabasal keratin promoter. Cell 62: 697–708PubMedGoogle Scholar
  22. Baker SJ, Preisinger AC, Jessup JM (1990) p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 50: 7717–7722Google Scholar
  23. Bakkenist CJ, Kastan MB (2003) DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421: 499–506PubMedGoogle Scholar
  24. Balmain A (2002) Cancer as a complex genetic trait:tumor susceptibility in humans and mouse models. Cell 108: 145–152PubMedGoogle Scholar
  25. Bannister AJ,Zegerman P, Partridge JF et al. (2001) Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature 410: 120–124Google Scholar
  26. Barbacid M (1987) ras genes. Ann Rev Biochem 56:779–827Google Scholar
  27. Bar-Sagi D (2001) A Ras by any other name. Moll Cell Biol 21: 1441–1443Google Scholar
  28. BartekJ, Lukas J (2001) Are all cancer genes equal? Nature 411: 1001–1002Google Scholar
  29. Bartolomei MS, Tilghman SM (1997) Genomic imprinting in mammals. Annu Rev Genet 31: 493–525PubMedGoogle Scholar
  30. Bartram CR (1996) Molecular genetic aspects of myelodysplastic syndromes. Semin Hematol 33: 139–149PubMedGoogle Scholar
  31. Bartram CR, de Klein A, Hagemeijer A et al. (1983) Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 306: 277–280PubMedGoogle Scholar
  32. Bassing CH, Swat W, Alt FW (2002) The mechanism and regulation of chromosomal V(D)J recombination. Cell 109: S45 - S55PubMedGoogle Scholar
  33. Bates S, Phillips AC,Clark PA et al. (1998) p14ARF links the tumor suppressors RB and p53. Nature 395: 124–125Google Scholar
  34. Baumann P,Cech TR (2001) Pot 1, the putative telomere end-binding protein in fission yeast and humans. Science 292: 1171–1175Google Scholar
  35. Baylin SB, Herman JG (2000) DNA hypermethylation in tumorigenesis:epigenetics joins genetics.Trends Genet 16: 168–174Google Scholar
  36. Baylin SB, Herman JG,GraffJR et al. (1998) Alterations in DNA methylation: a fundamental aspect of neoplasia.Adv Cancer Res 72: 141–196Google Scholar
  37. Belinsky SA, Nikula KJ, Palmisano WA et al. (1998) Aberrant methylation of p16INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 95: 11891–11896PubMedGoogle Scholar
  38. Bell, DW,Varley JM, Szydlo TE et al. (1999) Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286: 2528–2531Google Scholar
  39. Bemark M, Neuberger MS (2000) The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt’s lymphoma line. Oncogene 19: 3404–3410PubMedGoogle Scholar
  40. Benedict WF, Murphree AL, Banerjee A et al. (1983) Patient with 13 chromosome deletion: evidence that the retinoblastoma gene is a recessive cancer gene. Science 219: 973–975PubMedGoogle Scholar
  41. Berger SL (2002) Histone modifications in transcriptional regulation. Curr Opin Genet Dev 12: 142–148PubMedGoogle Scholar
  42. Bhattacharjee A, Richards WG, Staunton J et al. (2001) Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl.Acad Sci USA 98: 13790–13795PubMedGoogle Scholar
  43. Bhattacharya SK, Ramchandani S,Cervoni N et aí. (1999) A mammalian protein with specific demethylase activity for mCpG DNA. Nature 397: 579–583Google Scholar
  44. Bian YS,Osterheld MC, Fontolliet C et al. (2002) p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett’s esophagus. Gastroenterology 122: 1113–1121Google Scholar
  45. Bird A (2001) Methylation talk between histones and DNA. Science 294: 2113–2115PubMedGoogle Scholar
  46. Bird AP, Wolffe AP (1999) Methylation-induced repression–belts, braces, and chromatin. Cell 99: 451–454PubMedGoogle Scholar
  47. BischoffJR, Kirn DH, Williams A et al. (1996) An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274: 373–376Google Scholar
  48. Bishop JM (1985) Viral oncogenes.Cell 42: 23–38Google Scholar
  49. Bishop JM (1991) Molecular themes in oncogenesis. Cell 64: 235–248PubMedGoogle Scholar
  50. Bittner M, Meltzer P, Chen Y et al. (2000) Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406: 536–540PubMedGoogle Scholar
  51. Black DL (2000) Protein diversity from alternative splicing: a challenge for bioinformatics and post-genome biology. Cell 103: 367–370PubMedGoogle Scholar
  52. Blackburn EH (2001) Switching and signaling at the telomere. Cell 106: 661–673PubMedGoogle Scholar
  53. Blanco JG, Dervieux T, Edick MJ et al. (2001) Molecular emergence of acute myeloid leukemia during treatment for acute lymphoblastic leukemia. Proc Natl Acad Sci USA 98: 10338–10343PubMedGoogle Scholar
  54. BlanderG,Kipnis J, Leal JFM et al. (1999) Physical and functional interaction between p53 and the Werner’s syndrome protein. J Biol Chem 274: 29463–29469Google Scholar
  55. Blume-Jensen P, HunterT (2001) Oncogenic kinase signalling. Nature 411: 355–365Google Scholar
  56. Blunt T, Finnie NJ,Taccioli GE et al. (1995) Defective DNA-dependent protein kinase activity is linked to V(D)J recombination and DNA repair defects associated with the murine scid mutation.Cell 80: 813–823Google Scholar
  57. Bocciardi R,Mograbi B, Pasini B et al.(1997)The multiple endocrine neoplasia type 2B point mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck.Oncogene.15:2257–2265Google Scholar
  58. Bochar DA,Wang L,Beniya H et al.(2000)BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell 102:257–265Google Scholar
  59. Bogenhagen DF (1999) Repair of mtDNA in vertebrates. Am J Hum Genet 64: 1276–1281PubMedGoogle Scholar
  60. Boguski MS, McCormick F (1993) Proteins regulating Ras and its relatives. Nature 366: 643–654PubMedGoogle Scholar
  61. Bollag G, Clapp DW, Shih S et al. (1996) Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nature Genet 12: 144–148PubMedGoogle Scholar
  62. Bongarzone I, Butti MG, Coronelli S et al. (1994) Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas.Cancer Res 54: 2979–2985Google Scholar
  63. Bos JL (1989) ras oncogenes in human cancer: a review. Cancer Res 49: 4682–4689Google Scholar
  64. BosJL (1998) All in the family? New insights and questions regarding inter-connectivity of Ras, Rap 1 and Ral. EMBO J 17: 6776–6782Google Scholar
  65. Bos JL, Fearon ER, Hamilton SR et al. (1987) Prevalence of ras gene mutations in human colorectal cancers. Nature 327: 293–297PubMedGoogle Scholar
  66. Botstein D, White RL,Skolnick M et aí. (1980) Construction ofa genetic linkage map in man using restriction fragment length polymorphisms. Am J Hum Genet 32: 314–331Google Scholar
  67. Bouchard C, Staller P, Eilers M (1998) Control of cell proliferation by Myc. Trends Cell Biol 8: 202–206PubMedGoogle Scholar
  68. Boumil RM, Lee JT (2001) Forty years of decoding the silence in X-chromosome inactivation. Hum Mol Genet 10: 2225–2232PubMedGoogle Scholar
  69. BoveriT (1914) Zur Frage der Entstehung malignerTumoren.Gustav Fischer, JenaGoogle Scholar
  70. Box NF, Duffy DL, Chen W et al. (2001) MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 69: 765–773PubMedGoogle Scholar
  71. Boxer LM, Dang CV (2001) Translocations involving c-myc and c-myc function. Oncogene 20: 5595–5610PubMedGoogle Scholar
  72. Boyd SD,Tsai KY, Jacks T (2000) An intact HDM 2 RING-finger domain is re- quired for nuclear exclusion of p53. Nature Cell Biol 2: 563–568Google Scholar
  73. Branford S, Rudzki Z,Walsh Set al. (2002) High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99: 3472–3475Google Scholar
  74. Brash DE, Rudolph JA, Simon JA et al. (1991) A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 88: 10124–10128PubMedGoogle Scholar
  75. BraungerJ, Schleithoff L,Schulz AA et al. (1997) Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site.Oncogene 14: 2619–2631Google Scholar
  76. Breit TM, Beishuizen A, Ludwig WD et al. (1993a) tal-1 deletions in T-cell acute lymphoblastic leukemia as PCR target for detection of minimal residual disease. Leukemia 7: 2004–2011Google Scholar
  77. BreitTM, Mol EJ,Wolvers-Tettero ILM et al. (1993b) Site-specific deletions involving the tal-1 and sil genes are restricted to cells of the cell receptor a/(3 lineage: T cell receptor 8 gene deletion mechanism affects multiple genes.J Exp Med 177: 965–977Google Scholar
  78. Brison O, (1993) Gene amplification and tumor progression. Biochim Biophys Acta 1155: 25–41PubMedGoogle Scholar
  79. Brown J, Saracoglu K, Uhrig Set al. (2001) Subtelomeric chromosome rearrangements are detected using an innovative 12-color FISH assay ( M-TEL ). Nature Med 7: 497–501Google Scholar
  80. Brown L, Cheng JT, Chen Q et al. (1990) Site-specific recombination of the tal-1 gene is a common occurrence in human T cell leukemia. EMBO J 9: 3343–3351PubMedGoogle Scholar
  81. Brummelkamp TR, Bernards R, Agami R (2002) Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2: 243–247PubMedGoogle Scholar
  82. Bryan TM, Englezou A, Dalla-Pozza L et al. (1997) Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nature Med 3: 1271–1274PubMedGoogle Scholar
  83. Brzovic PS, Rajagopal P, Hoyt DW et al. (2001) Structure of a BRCA1–BARD1 heterodimeric RING-RING complex. Nature Struct Biol 8: 833–837PubMedGoogle Scholar
  84. Bulavin DV, Demidov ON,Saito S et al. (2002) Amplification of PPM 1 D in human tumors abrogates p53 tumor-suppressor activity. Nature Genet 31: 210–215PubMedGoogle Scholar
  85. Bunz F, Dutriaux A, Lengauer C et al. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497–1501PubMedGoogle Scholar
  86. Burghes AHM, Vaessin HEF, de la Chapelle A (2001) The land between mendelian and multifactorial inheritance. Science 293: 2213–2214PubMedGoogle Scholar
  87. Buschmann T, Fuchs SY, Lee CG et al. (2000) SUMO-1 modification of Mdm2 prevents its self-ubiquitination and increases Mdm2 ability to ubiquitinate p53. Cell 101: 753–762PubMedGoogle Scholar
  88. Bykov VJN, Issaeva N, Shilov A (2002) Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nature Med 8: 282–288PubMedGoogle Scholar
  89. Byrne JL, Marshall CJ (1998) The molecular pathophysiology of myeloid leukemias: Ras revisited. Br J Haematol 100: 256–264Google Scholar
  90. Caceres JF, Kornblihtt AR (2002) Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet 18: 186–193PubMedGoogle Scholar
  91. Cahill DP, Lengauer C, Yu J et al. (1998) Mutations of mitotic checkpoint genes in human cancers. Nature 392: 300–303PubMedGoogle Scholar
  92. Call KM,GlaserT, Ito CY et al. (1990) Isolation and characterization ofa zinc finger polypeptide gene at the human chromosome 11 Wilms’tumor locus. Cell 60: 509–520Google Scholar
  93. Canman CE, Lim DA,Cimprich KA et al. (1998) Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281: 1677–1679PubMedGoogle Scholar
  94. Cannon-Albright LA, Skolnick MH, Bishop DT et al. (1988) Common inheritance of susceptibility to colonic adenomatous polyps and associated colorectal cancers. N Engl J Med 319: 533–537PubMedGoogle Scholar
  95. Cantor SB, Bell DW,Ganesan S et aí. (2001) BACH1,a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cel 1105: 149–160Google Scholar
  96. Carlomagno F, Salvatore G, Cirafici AM et al. (1997) The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype.Cancer Res 57: 391–395PubMedGoogle Scholar
  97. Carlson BA, Dubay MM,Sausville EA et al. (1996) Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 56: 2973–2978PubMedGoogle Scholar
  98. Carlson B, Lahusen T, Singh Set al. (1999) Down-regulation of cycíin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res 59: 4634–4641PubMedGoogle Scholar
  99. Carnero A, Hudson JD, Price CM et al. (2000) p16INK4a and p19ARF act in overlapping pathways in cellular immortalization. Nature Cell Biol 2: 148–155Google Scholar
  100. Cartegni L, Chew SL, Krainer AR (2002) Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nature Rev Genet 3: 285–298PubMedGoogle Scholar
  101. Cassidy SB, Dykens E, Williams CA (2000) Prader-Willi and Angelman syndromes: sister imprinted disorders. Am J Med Genet 97: 136–146PubMedGoogle Scholar
  102. Cavé H, van der Werff ten Bosch J, Suciu Set al. (1998) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia.N Engl J Med 339: 591–598Google Scholar
  103. Cayuela JM,Gardie B, Sigaux F (1997) Disruption of the multiple tumor suppressor gene MTS1/p161NK4a/CDKN2 by illegitimate V(D)J recombinase activity in T-cell acute lymphoblastic leukemias. Blood 90: 3720–3726Google Scholar
  104. Chaganti RSK, Schonberg S, German J (1974) A manyfold increase in sister chromatid exchanges in Bloom’s syndrome lymphocytes. Proc Natl Acad Sci USA 71: 4508–4512PubMedGoogle Scholar
  105. Chan TA, Hermeking H, Lengauer C et al. (1999) 14–3–3o is required to prevent mitotic catastrophe after DNA damage. Nature 401: 616 – 620Google Scholar
  106. Chang F, Syrjänen S, Syrjänen K (1995) Implications of the p53 tumor-suppressor gene in clinical oncology.J Clin Oncol 13: 1009–1022Google Scholar
  107. Chellappan SP, Hiebert S, Mudryi M et al. (1991) The E2F transcription factor is a cellular target for the RB protein. Cell 65: 1053–1061PubMedGoogle Scholar
  108. Chen HL, Carbone DP (1997) p53 as a target for anti-cancer immunotherapy. Mol Med Today 4: 160–167Google Scholar
  109. Chen X (1999) The p53 family: same response, different signals? Mol Med Today 5: 387–392PubMedGoogle Scholar
  110. Chen YNP, Sharma SK, Ramsey TM et al. (1999) Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci USA 96: 4325–4329PubMedGoogle Scholar
  111. Chen YQ, Hsieh JT,Yao F et al. (1999) Induction of apoptosis and G2/M cell cycle arrest by DDC.Oncogene 18: 2747–2754Google Scholar
  112. Chin L, Pomerantz J, DePinho RA (1998) The INK4a/ARF tumor suppressor: one gene–two products–two pathways.TIBS 23: 291–296Google Scholar
  113. Chin L,Artandi SE, Shen Q et al.(1999a) p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cel 197: 527–538Google Scholar
  114. Chin L,Tam A, Pomerantz J et al. (1999b) Essential role for oncogenic Ras in tumour maintenance. Nature 400: 468–471Google Scholar
  115. Chinnery PF, Turnbull DM (2000) Mitochondria) DNA mutations in the pathogenesis of human disease. Mol Med Today 6: 425–431PubMedGoogle Scholar
  116. Cho KR,Oliver JD, Simons JW et al.(1994)The DDC gene:structural analysis and mutations in colorectal carcinomas.Genomics 19,525–531Google Scholar
  117. Choy E,Chiu VK,Silletti J et aí.(1999) Endomembrane trafficking of Ras:theGoogle Scholar
  118. CAAX motif targets proteins to the Er and Golgi.Cell 98:69–80Google Scholar
  119. Citterio E, Vermeulen W, Hoeijmakers JHJ (2000) Transcriptional healing. Cell 101: 447–450PubMedGoogle Scholar
  120. Coffey MC, Strong JE, Forsyth PS et al. (1998) Reovirus therapy of tumors with activated Ras pathway. Science 282: 1332–1334PubMedGoogle Scholar
  121. Cohen GB, Ren R, Baltimore D (1995) Modular binding domains in signal transduction proteins.Cell80:237–248Google Scholar
  122. Cohn SL (1999) Diagnosis and classification of the small round-cell tumors of childhood. Am J Pathol 155: 11–15PubMedGoogle Scholar
  123. Coller HA, Khrapko K, Bodyak ND et al. (2001) High frequency of homoplasmic mitochondrial DNA mutations in human tumors can be explained without selection. Nature Genet 28: 147–150PubMedGoogle Scholar
  124. Comings DE (1973) A general theory of carcinogenesis. Proc Natl Acad Sci USA 70: 3324–3328PubMedGoogle Scholar
  125. Conacci-Sorrell M,ZhurinskyJ,Ben-Ze’evA (2002)The cadherin-catenin adhesion system in signaling and cancer.J Clin Invest 109:987–991Google Scholar
  126. Contente A, Dittmer A, Koch MC et al. (2002) A polymorphic microsatellite that mediates induction of PIGS by p53. Nature Genet 30: 315–320PubMedGoogle Scholar
  127. Coppes MJ, Haber DA, Grundy PE (1994) Genetic events in the development of Wilms’tumor. N Engl J Med 331: 586–590PubMedGoogle Scholar
  128. Cordon-Cardo C (1995) Mutation of cell cycle regulators: biological and clinical implications for human neoplasia. Am J Pathol 147: 545–560PubMedGoogle Scholar
  129. Cortez D, Elledge SJ (2000) Conducting the mitotic symphony. Nature 406: 354–356PubMedGoogle Scholar
  130. Costello JF,Vertino PM (2002) Methylation matters:a new spin on maspin. Nature Genet 31: 123–126Google Scholar
  131. Costello JF, Frühwald MC, Smiraglia DJ et al. (2000) Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nature Genet 25: 132–138Google Scholar
  132. Cui H, Horon IL, Ohlsson R et al. (1998) Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nature Med 4: 1276–1279PubMedGoogle Scholar
  133. Cunningham JM, Christensen ER,Tester DJ et al. (1998) Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 58: 3455–3460PubMedGoogle Scholar
  134. Cuthbert AP, Fisher SA, Mirza MM et al. (2002) The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 122: 867–874PubMedGoogle Scholar
  135. Czene K, Lichtenstein P, Hemminki K (2002) Environmental and heritable causes of cancer among 9.6 million individuals in the Swedish family-cancer database.lnt J Cancer 99: 260–266Google Scholar
  136. Damm K, Hemmann U, Garin-Chesa P et al. (2001) A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J 20: 6958–6968PubMedGoogle Scholar
  137. D’Amours D, Jackson SP (2002) The MRE11 complex: at the crossroads of DNA repair and checkpoint signalling. Nature Rev Mol Cell Biol 3: 317–327Google Scholar
  138. D’Andrea AD, Grompe M (2003) The Fanconi anaemia/BRCA pathway. Nature Rev Genet 3: 23–34Google Scholar
  139. Dang CV (1999) c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 19:1–11Google Scholar
  140. Davies AA, Masson JY, Mcllwraith MJ et al. (2001) Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol Cell 7: 273–282PubMedGoogle Scholar
  141. D’Cruz CM, Gunther EJ, Boxer RB et al. (2001) c-MYC induces mammary tumorigenesis by means ofa preferred pathway involving spontaneous Kras2 mutations. Nature Med 7: 235–239Google Scholar
  142. De Azevedo WF, Mueller-Dieckmann HJ, Schulze-Gahmen U et al. (1996) Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2,a cell cycle kinase.Proc Natl Acad Sci USA 93: 2735–2740Google Scholar
  143. de Klein A, van Kessel AG, Grosveld G et al. (1982) A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 300: 765–767PubMedGoogle Scholar
  144. DeBaun MR, Niemitz EL, McNeil DE et al. (2002) Epigenetic alterations of H19 and LIT1 distinguish patients with Beckwith-Wiedemann syndrome with cancer and birth defects. Am J Hum Genet 70: 604–611PubMedGoogle Scholar
  145. Deininger MWN, Goldman JM, Melo JV (2000a) The molecular biology of chronic myeloid leukemia. Blood 96: 3343–335PubMedGoogle Scholar
  146. Deininger MWN,Vieira S, Mendiola R et al. (2000b) BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia.Cancer Res 60: 2049–2055Google Scholar
  147. Delattre O, Zucman J, Melot T et al. (1994) The Ewing family of tumors–a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 331: 294–299PubMedGoogle Scholar
  148. Demetri GD, von Mehren M, Blanke CD et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472–480PubMedGoogle Scholar
  149. Denissenko MF, Pao A, Tang M et al. (1996) Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science 274: 430–432PubMedGoogle Scholar
  150. Denu JM, Stuckey JA, Saper MA et al. (1996) Form and function in protein dep hosphorylation. Cel 187: 361–364Google Scholar
  151. Desai KV, Xiao N, Wang W et al. (2002) Initiating oncogenic event determines gene-expression patterns of human breast cancer models. Proc Natl Acad Sci USA 99: 6967–6972PubMedGoogle Scholar
  152. Devilee P (1999) BRCA1 and BRCA2 testing:weighing the demand against the benefits. Am J Hum Genet 64: 943–948PubMedGoogle Scholar
  153. Dhanasekaran SM, Barrette TR, Ghosh D et al. (2001) Delineation of prognostic biomarkers in prostate cancer. Nature 412: 822–826PubMedGoogle Scholar
  154. Di Croce L, Raker VA, Corsaro M et al. (2002) Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295: 1079–1082PubMedGoogle Scholar
  155. DiCiommo D, Gallie BL, Bremner R (2000) Retinoblastoma: the disease, gene and protein provide critical leads to understand cancer. Sem Cancer Biol 10: 255–269Google Scholar
  156. Dietrich WF, Lander ES, Smith JS et al. (1993) Genetic identification of Mom-1,a major modifier locus affecting min-induced intestinal neoplasia in the mouse. Cell 75: 631–639PubMedGoogle Scholar
  157. Dong DL, Liu R, Sherlock R et al. (1999) Molecular forceps from combinatorial libraries prevent the farnesylation of Ras by binding to its carboxyl terminus.Chem Biol 6: 133–141Google Scholar
  158. Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nature Rev Cancer 3: 11–22Google Scholar
  159. Drews J (2000) Drug discovery: a historical perspective. Science 287: 1960–1964PubMedGoogle Scholar
  160. Druker B1 (2002) Perspectives on the development of a molecularly targeted agent.Cancer Cell 1: 31–36Google Scholar
  161. Druker BJ, Sawyers CL, Kantarjian H et al. (2001 a) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344: 1038–1042Google Scholar
  162. Druker BJ,Talpaz M, Resta DJ et al. (2001 b) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031–1037Google Scholar
  163. Dudley DT, Pang L, Decker Si et al. (1995) A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 92: 7687–7689Google Scholar
  164. Dunham MA, Neumann AA, Fasching LC et al. (2000) Telomere mainte- nance by recombination in human cells. Nature Genet 26: 447–450PubMedGoogle Scholar
  165. Duval A, Hamelin R (2002) Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability. Cancer Res 62: 2447–2454PubMedGoogle Scholar
  166. Duval A, Gayet J, Zhou XP et al. (1999) Frequent frameship mutations of the TCF-4 gene in colorectal cancers with microsatellite instability.Cancer Res 59: 4213–4215Google Scholar
  167. Duval A, Rolland S, Compoint A et al. (2001) Evolution of instability at coding and non-coding repeat sequences in human MSI-H colorectal cancers. Hum Mol Genet 10: 513–518PubMedGoogle Scholar
  168. Early Breast Cancer Trialists’ Collaborative Group (1998 a) Tamoxifen for early breast cancer:an overview of the randomized trials. Lancet 351: 1451–1467Google Scholar
  169. Early Breast Cancer Trialists’ Collaborative Group (1998b) Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 352: 930–942Google Scholar
  170. Eberhart CE, Coffey RJ, Radhika A et al. (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183–1188PubMedGoogle Scholar
  171. Eddy SR (2001) Non-coding RNA genes and the modern RNA world. Nature Rev Genet 2: 919–929PubMedGoogle Scholar
  172. Edery P, Lyonnet S, Mulligan LM et al. (1994) Mutations of the RET proto-oncogene in Hirschsprung’s disease. Nature 367: 378–380PubMedGoogle Scholar
  173. Egan SE, Giddings BW, Brooks MW et al. (1993) Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation. Nature 363: 45–51PubMedGoogle Scholar
  174. Ehrlich M (2002) DNA methylation in cancer: too much, but also too little. Oncogene 21: 5400–5413PubMedGoogle Scholar
  175. Elbashir SM, Harborth J, Lendeckel W et al. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494–498PubMedGoogle Scholar
  176. EI-Deiry WS (1998) Regulation of p53 downstream genes. Sem Cancer Biol 8: 345–357Google Scholar
  177. Ellis CN, Ellis MB, Blakemore WS (1987) Effect of adriamycin on heart mitochondria) DNA. Biochem J 245: 309–312PubMedGoogle Scholar
  178. Ellis NA, Groden J, Ye ZH et al. (1995) The Bloom’s syndrome gene product is homologous to RecQ helicases. Cell 83: 655–666PubMedGoogle Scholar
  179. Enard W, Khaitovich P, Klose J et al. (2002) Intra- and interspecific variation in primate gene expression patterns. Science 296: 340–343PubMedGoogle Scholar
  180. Eng C (1996) The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung’s disease. N Engl J Med 335: 943–951PubMedGoogle Scholar
  181. Eppert K, Scherer SW,Ozcelik H et al. (1996) MADR2 maps to 18g21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 86: 543–552PubMedGoogle Scholar
  182. Epstein CJ, Martin GM, Schultz AL et al. (1966) Werner’s syndrome:a review of its symptomatology, natural history, pathologic features, genetics and relationship to the natural aging process. Medicine 45: 177–221PubMedGoogle Scholar
  183. Esteller M (2002) CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 21: 5427–5440PubMedGoogle Scholar
  184. Esteller M,Catasus L,Matias-Guiu X et al.(1999) hMLH1 promoter hypermethylation is an early event in human endometrial tumorgenesis. Am J Pathol.155: 1 767–1771Google Scholar
  185. Esteller M, Silva JM, Dominguez G et al. (2000) Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.J Natl Cancer Inst 92: 564–569Google Scholar
  186. Esteller M, Corn PG, Baylin SB et al. (2001a) A gene hypermethylation profile of human cancer. Cancer Res. 61: 3225–3229PubMedGoogle Scholar
  187. Esteller M, Fraga MF, Gua M et al. (2001b) DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet 10: 3001–3007PubMedGoogle Scholar
  188. Evans WE, Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapeutics.Science 286: 487–491Google Scholar
  189. Fader) S, Talpaz M, Estrov Z et al. (1999) The biology of chronic myeloid leukemia. N Engl J Med 341: 164–172Google Scholar
  190. Falck J, Mailand N, SyljuSsen RG et al. (2001)The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 410: 842–847Google Scholar
  191. Falls JG, Pulford DJ, Wylie AA et al. (1999) Genomic imprinting: implications for human disease. Am J Pathol 154: 635–647PubMedGoogle Scholar
  192. Fantl WJ,Johnson DE,Williams LT(1993) Signalling by receptor tyrosine kinases.Annu Rev Biochem 62:453–481Google Scholar
  193. Fasano O, Birnbaum D, Edlund L et al. (1984) New human transforming genes detected by a tumorigenicity assay. Mol Cell Biol 4: 1695–1705PubMedGoogle Scholar
  194. Fasching K, Panzer K, Haas OA et al. (2000) Presence of clone-specific antigen receptor gene rearrangements at birth indicates an in utero origin of diverse types of early childhood acute lymphoblastic leukemia. Blood 95: 2722–2724PubMedGoogle Scholar
  195. Favata MF, Horiuchi KY, Manos EJ et al. (1998) Identification of a novel inhibitor of mitogen-activated protein kinase kinase. Biol Chem 273: 18623–18632Google Scholar
  196. Feinberg AP (2000) The two-domain hypothesis in Beckwith-Wiedemann syndrome.J Clin Invest 106: 739–740Google Scholar
  197. Feinberg AP (2001) Cancer epigenetics takes center stage. Proc Natl Acad Sci USA 98: 392–394PubMedGoogle Scholar
  198. Feinberg AP,Vogelstein B (1983) Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301: 89–92Google Scholar
  199. Felsher DW, Bishop JM (1999) Reversible tumorgenesis by MYC in hematopoietic lineages. Mol Cell 4: 199–207PubMedGoogle Scholar
  200. Feraon ER,Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cel l 61: 759–767Google Scholar
  201. Ferguson DO, Alt FW (2001) DNA double strand break repair and chromosomal translocation: lessons from animal models. Oncogene 20: 5572–5579PubMedGoogle Scholar
  202. Fero ML, Randel E,Gurley KE et al.(1998)The murine gene p27K’Pl is haploinsufficient for tumour suppression. Nature 396: 177–180Google Scholar
  203. Ferrando AA, Neuberg DS, Staunton Jet al. (2002) Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 1: 75–87PubMedGoogle Scholar
  204. Finette BA, Poseno T, Albertini RJ (1996) V(D)J recombinase-mediated HPRT mutations in peripheral blood lymphocytes of normal children. Cancer Res 56: 1405–1412PubMedGoogle Scholar
  205. Finlay CA, Hinds PW, Levine Al (1989) The p53 proto-oncogene can act as a suppressor of transformation. Cell 57: 1083–1093PubMedGoogle Scholar
  206. Fishel R (2001(The selection for mismatch repair defects in hereditary nonpolyposis colorectal cancer: revising the mutator hypothesis. Cancer Res 61:7369–7374Google Scholar
  207. Fishel R, Kolodner RD (1995) Identification of mismatch repair genes and their role in the development of cancer. Curr Opin Genet Dev 5: 382–395PubMedGoogle Scholar
  208. Fisher GH,Wellen SL,Klimstra D etal. (2001) Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 15: 3249–3262Google Scholar
  209. Fliss MS, Usadel H, Caballero OL et al. (2000) Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 287: 2017–2019PubMedGoogle Scholar
  210. Flores ER,Tsai KY, Crowley D et al.(2002) p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416: 560–564Google Scholar
  211. Forastiere A, Koch W,Trotti A et al. (2001) Head and neck cancer. N Engl J Med 345: 1890–1900PubMedGoogle Scholar
  212. Foroni L, Harrison CJ, Hoffbrand AV et al. (1999) Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis. Br J Haematol 105: 7–24PubMedGoogle Scholar
  213. Foster BA, Coffey HA, Morin MJ et al. (1999) Pharmacological rescue of mu- tant p53 conformation and function.Science 286: 2507–2510Google Scholar
  214. Franchitto A, Pichierri P (2002) Protecting genomic integrity during DNA replication: correlation between Werner’s and Bloom’s syndrome gene products and the MRE11 complex. Hum Mol Genet 11: 24472453Google Scholar
  215. Friedler A, Hansson LO,Veprintsev DB et al. (2002) A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci USA 99: 937–942PubMedGoogle Scholar
  216. Friend SH, Bernards R, Rogelj S et al. (1986) A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323: 643–646PubMedGoogle Scholar
  217. Frizelle SP,Grim J,Zhou J et al. (1998) Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest,cell death,tumor suppression and tumor regression.Oncogene 16: 3087–3095Google Scholar
  218. Futaki M, Liu JM (2001) Chromosomal breakage syndromes and the BRCA1 genome surveillance complex.Trends Mol Med 7: 560–565Google Scholar
  219. Gabriel SB,Salomon R, Pelet A et al. (2002) Segregation at three loci explains familial and population risk in Hirschsprung’s disease. Nature Genet 31: 89–93Google Scholar
  220. Gale KB, Ford AM, Repp R et al. (1997) Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci USA 94: 13950–13954PubMedGoogle Scholar
  221. Gallie BL, Squire JA, Goddard A et al. (1990) Biology of disease. Mechanism of oncogenesis in retinoblastoma. Lab Invest 62: 394–408Google Scholar
  222. Ganesan S, Silver DP, Greenberg RA et al. (2002) BRCA1 supports XIST RNA concentration on the inactive X chromosome. Cell 111: 393–405PubMedGoogle Scholar
  223. Gangloff S, Soustelle C, Fabre F (2000) Homologous recombination is responsible for cell death in the absence of the Sgs1 and Srs2 helicases. Nature Genet 25: 192–194PubMedGoogle Scholar
  224. Gao Y, Ferguson DO,Xie W et al. (2000) Interplay of p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability and development. Nature 404: 897–900PubMedGoogle Scholar
  225. Garcia-Cao I,Garcia-Cao M, Martin-Caballero J et al. (2002)’Super p53’mice exhibit enhanced DNA damage response,are tumor resistant and age normally. EMBO J 21: 6225–6235Google Scholar
  226. Garcia-Higuera (,Taniguchi T, Ganesan Set al. (2001) Interaction of the Fan-coni anemia proteins and BRCA1 in a common pathway. Mol Cell 7: 249–262Google Scholar
  227. Gardie B, Cayuela JM, Martini S et al. (1998) Genomic alterations of the p19ARF encoding exons in T-cell acute lymphoblastic leukemia. Blood 91: 1016–1020PubMedGoogle Scholar
  228. Garinis GA, Patrinos GP, Spanakis NE et al. (2002) DNA hypermethylation: when tumour suppressor genes go silent. Hum Genet 111: 115127Google Scholar
  229. Gatei M,Young D, Cerosaletti KM et al. (2000) ATM-dependent phosphorylation of nibrin in response to radiation exposure. Nature Genet 25: 115–118Google Scholar
  230. Gavin AC, Bösche M, Krause R et al. (2002) Functional organization of the yeast proteome by systematic analysis of protein complexes. Nature 415: 141–147PubMedGoogle Scholar
  231. Gayther SA, Batley Si, Linger L et al. (2000) Mutations truncating the EP300 acetylase in human cancers. Nature Genet 24: 300–303PubMedGoogle Scholar
  232. German J (1993) Bloom syndrome:a mendelian prototype of somatic mutational disease. Medicine 72: 393–406PubMedGoogle Scholar
  233. Giardiello FM,Yang VW, Hylind LM et aí. 2002 ) Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 346: 1054–1059Google Scholar
  234. Gibbs JB (2000) Mechanism-based target identification and drug discovery in cancer research. Science 287: 1969–1973PubMedGoogle Scholar
  235. Gillert E, Leis T, Repp R et al. (1999) A DNA damage repair mechanism is involved in the origin of chromosomal tranaslocations t(4;11) in primary leukemic cells.Oncogene 18: 4663–4671Google Scholar
  236. Gleissner B,Gökbuget N, Bartram CR et al. (2002) Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 99: 1536–1543Google Scholar
  237. Goh HS,Yao J, Smith DR (1995) p53 point mutation and survival in colorectal cancer patients.Cancer Res 55:5217–5221Google Scholar
  238. Goldberg Z, Sionov RV, Berger M et al. (2002) Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation. EMBO J 21: 37153727Google Scholar
  239. Goldhirsch A, Glick JH, Gelber RD et al. (1998) Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 90: 1601–1608PubMedGoogle Scholar
  240. Goldstein AM, Fraser MC, Struewing JP et al. (1995) Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4a mutations. N Engl J Med 333: 970–974PubMedGoogle Scholar
  241. GolubTR,Slonim DK,Tamayo P et al. (1999) Molecular classification of cancer:class discovery and class prediction by gene expression monitoring. Science 286: 531–537Google Scholar
  242. Gong JG, Costanzo A,Yang HQ et al. (1999) The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399: 806–808PubMedGoogle Scholar
  243. GoossensT, Klein U, Kiippers R (1998) Frequent occurrence of deletions and duplications during somatic hypermutation: implications for oncogene translocations and heavy chain disease. Proc Natl Acad Sci USA 95: 2463–2468Google Scholar
  244. Gorlick R, Goker E,Trippett T et al. (1996) Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 335: 1041–1048PubMedGoogle Scholar
  245. Gorre ME, Mohammed M, Ellwood K et al. (2001) Clinical resistance to STI571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876–880PubMedGoogle Scholar
  246. Gottesman MM, Pastan I, Ambudkar SV (1996) P-glycoprotein and multidrug resistance.Curr Opin Genet Dev 6: 610–617Google Scholar
  247. Gowen LC,Avrutskaya AV, Latour et al. (1 998(BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science 281: 1009–1012Google Scholar
  248. Graveley BR (2001) Alternative splicing: increasing diversity in the proteomic world.Trends Genet 17: 100–107Google Scholar
  249. Grawunder U,Zimmer D, Fugmann Set al. (1998) DNA ligase IV is essential for V(D)J recombination and DNA double-strand break repair in human precursor lymphocytes. Mol Cell 2: 477–484Google Scholar
  250. Gray MD, Shen JC, Kamath-Loeb AS et al. (1997) The Werner syndrome protein is a DNA helicase. Nat Genet 17: 100–103PubMedGoogle Scholar
  251. Gray NS, Wodicka L, Thunnissen AM et al. (1998) Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281: 533–538PubMedGoogle Scholar
  252. Greenblatt MS, Bennett WP, Hollstein M et al. (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855–4878PubMedGoogle Scholar
  253. Greider CW (1999) Telomeres do D-Loop-T-Loop. Cel l 97: 419–422Google Scholar
  254. Griffith JD, Comeau L, Rosenfield Set al. (1999) Mammalian telomeres end in a large duplex Ioop.Cell 97: 503–514Google Scholar
  255. Grignani F, De Matteis S, Nervi C et al. (1998) Fusion proteins of the retinoic acid receptor-a recruit histone deacetylase in promyelocytic leukemia. Nature 391: 815–818PubMedGoogle Scholar
  256. Groden J,Thliveris A, Samowitz W et al. (1991) Identification and characterization of the familial adenomatous polyposis coli gene. Cell 66: 589–600Google Scholar
  257. Groffen J,Stephenson JR, Heisterkamp N et a1. (1984) Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36: 93–99Google Scholar
  258. Grompe M, D’Andrea AD (2001) Fanconi anemia and DNA repair. Hum Mol Genet 10: 2253–2259PubMedGoogle Scholar
  259. Gu W, Roeder RG (1997) Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90: 595–606PubMedGoogle Scholar
  260. Haber DA, Fearon ER (1998)The promise of cancer genetics. Lancet 351: 1–8Google Scholar
  261. Hafen E (1998) Kinases and phosphatases–a marriage is consummated. Science 280: 1212–1213PubMedGoogle Scholar
  262. Hahn SA, Schutte M, Hogue AT et al. (1996) DPC4, a candidate tumor suppressor gene at human chromosome 18g21.1. Science 271: 350–353PubMedGoogle Scholar
  263. Hahn WC,Weinberg RA (2002) Rules for making human tumor cells. N Engl Med 347: 1593–1603Google Scholar
  264. Hahn WC,CounterCM,Lundberg AS etal. (1999) Creation of human tumour cells with defined genetic elements. Nature 400: 464–468Google Scholar
  265. Hainaut P, Pfeifer GP (2001) Patterns of p53 G-)T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke.Carcinogenesis 22: 367–374Google Scholar
  266. Halfon MS,Carmena A,Gisselbrecht S (2000) Ras pathway specificity is determined by the integration of multiple signal-activated and tissue-restricted transcription factors.Cell 103: 63–74Google Scholar
  267. Hallek M, Bergsagel PL, Anderson KC (1998) Multiple myeloma: increasing evidence for a multistep transformation process. Blood 91: 3–21PubMedGoogle Scholar
  268. Hampe J, Grebe J, Nikolaus S et al. (2002) Association of NOD2 (CARD 15) genotype with clinical course of Crohn’s disease: a cohort study. Lancet 359: 1661–1665PubMedGoogle Scholar
  269. Hanada M, Delia D, Aiello A et al. (1993) bc1–2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 82: 1820–1828Google Scholar
  270. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57–70PubMedGoogle Scholar
  271. Hanausek M, Ganesh P, Walaszek Z et al. (2001) Avicins, a family of triterpenoid saponins from Acacia victoriae (Bentham), suppress H-ras mutations and aneuploidy in a murine skin carcinogenesis model. Proc Natl Acad Sci USA 98: 11551–11556PubMedGoogle Scholar
  272. Hann BC, Lane DP (1995) The dominating effect of mutant p53. Nature Genet 9: 221–222PubMedGoogle Scholar
  273. Hansen RS,Wijmenga C, Luo Pet al. (1999) The DNMT3B DNA methyltransferase gene is mutated in the ICF immunodeficiency syndrome. Proc Natl Acad Sci USA 96: 14412–14417Google Scholar
  274. Hark AT, Schoenherr CJ, Katz DJ et al. (2000) CTCF mediates methylationsensitive enhancer-blocking activity at the H19/Igf2 locus. Nature 405: 486–489PubMedGoogle Scholar
  275. Harris H (1988) The analysis of malignancy by cell fusion: the position in 1988. Cancer Res 48: 3302–3306PubMedGoogle Scholar
  276. Harris H, Miller OJ, Klein G et al. (1969) Suppression of malignancy by cell fusion. Nature 223: 363–368PubMedGoogle Scholar
  277. Hashizume R, Fukuda M, Maeda I et al. (2001) The RING heterodimer BRCA1–BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation.) Biot Chem 276: 14537–14540Google Scholar
  278. Haupt Y, Maya R, Kazaz A et al. (1997) Mdm2 promotes the rapid degradation of p53. Nature 387: 296–299PubMedGoogle Scholar
  279. He LZ,TolentinoT,Grayson Petal. (2001) Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelotic Ieukemia.J Clin Invest 108: 1321–30Google Scholar
  280. He TC, Sparks AB, Rago C et al. (1998) Identification of c-MYC as a target of the APC pathway. Science 281: 1509–1512PubMedGoogle Scholar
  281. Heard E, Rougeulle C, Arnaud D et al. (2001) Methylation of histone H3 at Lys-9 is an early mark on the X chromosome during X inactivation.Cell 107: 727–738Google Scholar
  282. Hedenfalk I, Duggan D, Chen Y et al. (2001) Gene-expression profiles in hereditary breast cancer. N Engl J Med 344: 539–548PubMedGoogle Scholar
  283. Heighway J, Hasleton PS (1986) c-Ki-ras amplification in human lung cancer. Br J Cancer 53: 285–287Google Scholar
  284. Heinrich MC, Blanke CD, Druker BJ et al. (2002) Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20: 1692–1703PubMedGoogle Scholar
  285. Heldin CH (1995) Dimerization of cell surface receptors in signal transduction. Cel 180: 213–223Google Scholar
  286. Hellman A, Zlotorynski E, Scherer SW et al. (2002) A role for common fragile site induction in amplification of human oncogenes.Cancer Cell 1: 89–97Google Scholar
  287. Hemminki A, Markie D,Tomlinson I et al. (1998) A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 391: 184–187PubMedGoogle Scholar
  288. Hendrich B,Bickmore W (2001) Human diseases with underlying defects in chromatin structure and modification. Hum Mol Genet 20: 2233–2242Google Scholar
  289. Hendrix MJC (2000) De-mystifying the mechanism(s) of maspin. Nature Med 6: 374–376PubMedGoogle Scholar
  290. Herman JG,Latif F,Wenig Y et al. (1994) Silencing of theVHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 91: 9700–9704Google Scholar
  291. Herman JG, Merlo A, Mao L et al. (1995) Inactivation of the CDKN2/p16/ MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.Cancer Res 55: 4525–4530Google Scholar
  292. Herman JG, Umar A, Polyak K et al. (1998) Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 95: 6870–6875PubMedGoogle Scholar
  293. Herrmann C, Block C, Geisen C et al. (1998) Sulindac sulfide inhibits Ras signaling.Oncogene 17: 1769–1776Google Scholar
  294. Hietanen S, Lain S, Krausz E et al. (2000) Activation of p53 in cervical carcinoma cells by small molecules. Proc Natl Acad Sci USA 97: 8501–8506PubMedGoogle Scholar
  295. Hilgers W, Kern SE (1999) Molecular genetic basis of pancreatic adenocarcinoma.Genes Chromosomes Cancer 26: 1–12Google Scholar
  296. Hiom K, Melek M, Gellert M (1998) DNA transposition by the RAG1 and RAG2 proteins:a possible source of oncogenic translocations.Cell 94: 463–470Google Scholar
  297. Hirama T, Koeffler HP (1995) Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 86: 841–854PubMedGoogle Scholar
  298. Hirao A, Kong YY, Matsuoka S et al. (2000) DNA damage induced activation of p53 by the checkpoint kinase Chk2. Science 287: 1824–1827PubMedGoogle Scholar
  299. Hochstraßer M (1996) Ubiquitin-dependent protein degradation. Annu Rev Genet 30: 405–439PubMedGoogle Scholar
  300. Hodes R (2001) Molecular targeting of cancer:Telomeres as targets. Proc Natl Acad Sci USA 98: 7649–7651PubMedGoogle Scholar
  301. Hoeijmakers JHJ (2001) Genome maintenance mechanisms for preventing cancer. Nature 411: 366–374PubMedGoogle Scholar
  302. Hofmann WK,de Vos S, Elashoff D et al. (2002a) Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. Lancet 359: 481–486Google Scholar
  303. Hofmann WK, Jones LC, Lemp NA et al. (2002b) Ph acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 99: 1860–1862PubMedGoogle Scholar
  304. Hollstein M,Sidransky D,Vogelstein Bet al. (1991) p53 mutations in human cancer. Science 253:49–53Google Scholar
  305. Holyoake TL (2001) Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory. Br J Haematol 113: 11–23PubMedGoogle Scholar
  306. Hong WK, Sporn MB (1997) Recent advances in chemoprevention of cancer. Science 278: 1073–1077PubMedGoogle Scholar
  307. Hooper ML (1998) Tumor suppressor gene mutations in humans and mice: parallels and contrasts. EMBO J 17: 6783–6789PubMedGoogle Scholar
  308. Houlston RS, Tomlinson IPM (2000) Detecting low penetrance genes in cancer:the way ahead.J Med Genet 37: 161–167Google Scholar
  309. Howe JR, Roth S, Ringold JC et al. (1998) Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science 280: 1086–1088PubMedGoogle Scholar
  310. Howlett NG,Taniguchi T, Olson S et al. (2002) Billelic inactivation of BRCA2 in Fanconi anemia. Science 297: 606–609Google Scholar
  311. Hsu HL, Gilley D, Blackburn EH et al. (1999) Ku is associated with the telomere in mammals. Proc Natl Acad Sci USA 96: 12454–12458PubMedGoogle Scholar
  312. Hsu IC, Metcalf RA, Sun T et al. (1991) Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350: 427–428PubMedGoogle Scholar
  313. Huang J, Papadopoulos N, McKinley Ai et al. (1996) APC mutations in colorectal tumors with mismatch repair deficiency. Proc Natl Acad Sci USA 93: 9049–9054Google Scholar
  314. Huettner CS, Zhang P, van Etten RA et al. (2000) Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nature Genet 24: 57–60PubMedGoogle Scholar
  315. Hunter T (1995) Protein kinases and phosphatases: the Ying and Yang of protein phosphorylation and signaling. Cell 80: 225–236PubMedGoogle Scholar
  316. Hunter (1997) Oncoprotein networks. Cell 88: 333–346PubMedGoogle Scholar
  317. HunterT (2000) Signaling-2000 and beyond.Cell 100: 113–127Google Scholar
  318. Hunter T, Pines J (1994) Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cel l 79: 573–582Google Scholar
  319. Huse M, Kuriyan J (2002) The conformational plasticity of protein kinases. Cell 109: 275–282PubMedGoogle Scholar
  320. Hussain SP, Harris CC (1998) Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res 58: 4023–4037PubMedGoogle Scholar
  321. Husson SM, Hughes RAC (1994) The neurofibromatoses: a pathogenetic and clinical overview.Chapman and Hall, LondonGoogle Scholar
  322. Hussussian CJ, Struewing JP, Goldstein AM et al. (1994) Germline p16 mutations in familial melanoma. Nature Genet 8: 15–21PubMedGoogle Scholar
  323. Ichikawa A, Kinoshita R,WatanabeTet aí. (1997) Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 337: 529–534Google Scholar
  324. Igney FH, Krammer PH (2002) Death and anti-death: tumour resistance to apoptosis. Nature Rev Cancer 2: 277–288Google Scholar
  325. Imamura J, Miyoshi I, Koeffler HP (1994) p53 in hematologic malignancies. Blood 84: 2412–2421Google Scholar
  326. International Human Genome Sequencing Consortium (2001) Initial sequencing and analysis of the human genome. Nature 409: 860–921Google Scholar
  327. lonov Y, Peinado MA, Malkhosyan Set al. (1993) Ubiquitous somatic mutations in single repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363: 558–561Google Scholar
  328. lonovY,Yamamoto H,Krajewski Setal. (2000) Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution. Proc Natl Acad Sci USA 97: 10872–10877Google Scholar
  329. Irby RB, Mao W, Coppola D et al. (1999) Activating SRC mutation in a subset of advanced human colon cancers. Nature Genet 21: 187–190PubMedGoogle Scholar
  330. Irwin M,Marin MC, Phillips AC et al. (2000) Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature 407: 645–648Google Scholar
  331. Jacobson S, Pillus L (1999) Modifying chromatin and concepts of cancer. Curr Opin Genet Dev 9: 175–184PubMedGoogle Scholar
  332. Jänne PA, Mayer RJ (2000) Chemoprevention of colorectal cancer. N Engl J Med 342: 1960–1968PubMedGoogle Scholar
  333. Jain M, Arvanitis C, Chu K et al. (2002) Sustained loss of a neoplastic phenotype by brief inactivation of MYC.Science 297: 102–104Google Scholar
  334. Jallepalli PV,Waizenegger IC, Bunz F et al. (2001) Securin is required for chromosomal stability in human cells. Cell 105: 445–457Google Scholar
  335. Jansen B, Schlagbauer-Wadl H, Kahr H et al. (1999) Novel Ras antagonist blocks human melanoma growth. Proc Natl Acad Sci USA 96: 14019–14024PubMedGoogle Scholar
  336. Jenuwein T, Allis CD (2001) Translating the histone code. Science 293: 1074–1080PubMedGoogle Scholar
  337. Jin X, Nguyen D, Zhang WW et al. (1995) Cell cycle arrest and inhibition of tumor cell proliferation by the p161NK4a gene mediated by an adenovirus vector. Cancer Res 55: 3250–3253PubMedGoogle Scholar
  338. Jiricny J, Nyström-Lahti M (2000) Mismatch repair defects in cancer. Curr Opin Genet Dev 10: 157–161PubMedGoogle Scholar
  339. Joenje H, Patel KJ (2001)The emerging genetic and molecular basis of Fan-coni anemia. Nature 2: 446–457Google Scholar
  340. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al. (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344: 1052–1056PubMedGoogle Scholar
  341. Johnson CA (2000) Chromatin modification and disease.J Med Genet 37: 905–915Google Scholar
  342. Johnson L, Mercer K, Greenbaum D et al. (2001) Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410: 1111–1116PubMedGoogle Scholar
  343. Johnson RE,Kondratick CM, Prakash S et al.(1999) hRAD30 mutations in the variant form of xeroderma pigmentosum. Science 285: 263–265Google Scholar
  344. Jonason A, Kunala S, Price GJ et al. (1996) Frequent clones of p53-mutated keratinocytes in normal human skin. Proc Natl Acad SCI USA 93: 14025–14029PubMedGoogle Scholar
  345. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nature Rev Genet 3: 415–428PubMedGoogle Scholar
  346. Jones PA, Laird PW (1999) Cancer epigenetics comes of age. Nature Genet 21: 163–167PubMedGoogle Scholar
  347. Jones S,Emmerson P, Maynard J et al. (2002) Biallelic germline mutations in MYH predispose to multiple colorectal adenoma and somatic G:C-T:A mutations. Hum Mol Genet 11: 2961–2967Google Scholar
  348. Jonkers J, Berns A (2002) Conditional mouse models of sporadic cancer. Nature Rev Cancer 2: 251–265Google Scholar
  349. Judson H, Hayward BE, Sheridan E et al. (2002) A global disorder of imprinting in the human female germ line. Nature 416: 539–542PubMedGoogle Scholar
  350. Jüttermann R, Li E, Jaenisch R (1994) Toxicity of 5-aza-2’-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA 91: 11797–11801PubMedGoogle Scholar
  351. Kadonaga JT (1998) Eukaryotic transcription: an interlaced network of transcription factors and chromatin-modifying machines. Cell 92: 307–313PubMedGoogle Scholar
  352. Kaghad M, Bonnet H, Yang A et al. (1997) Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90: 809–819PubMedGoogle Scholar
  353. Kallioniemi A, Kallioniemi OP, Sudar D et al. (1992) Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science258: 818–821Google Scholar
  354. Kanaar R, Hoeijmakers JHJ, van Gent DC (1998) Molecular mechanisms of DNA double-strand break repair.Trends Cell Biol 8: 483–489Google Scholar
  355. Karlseder J, Broccoli D, Dai Y et al. (1999) p53- and ATM-dependent apop- tosis induced by telomeres lacking TRF2. Science 283: 1321–1325Google Scholar
  356. Karow JK, Constantinou A, Li JL et al. (2000a) The Bloom’s syndrome gene product promotes branch migration of Holliday junctions. Proc Natl Acad Sci USA 97: 6504–6508PubMedGoogle Scholar
  357. Karow JK, Wu L, Hickson ID (2000b) RecQ family helicases: roles in cancer and aging.Curr Opin Genet Dev 10: 32–38Google Scholar
  358. Karuman P,Gozani O,Odze RD et al.(2001)The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell death. Mol Cell 7: 1307–1319Google Scholar
  359. Kastan MB, Lim DS (2000) The many substrates and functions of ATM. Nature Rev Mol Cell Biol 1: 179–186Google Scholar
  360. Katsanis N, Ansley Si, Badano JL (2001) Triallelic inheritance in BardetBiedl syndrome, a mendelian recessive disorder. Science 293: 2256–2259PubMedGoogle Scholar
  361. Katzenstein HM, Bowman LC, Brodeur GM et al. (1998) Prognostic significance of age,MYCNoncogene amplification,tumor cell ploidy,and histology in 110 infants with stage D(S) neuroblastoma:the pediatric oncology group experience-a pediatric oncology group study.) Clin On-col 16: 2007–2017Google Scholar
  362. Kawa K, Ohnuma N, Kaneko M et al. (1999) Long-term survivors of advanced neuroblastoma with MYCN amplification: a report of 19 patients surviving disease-free for more than 66 months.) Clin Oncol 10: 3216–3220Google Scholar
  363. Kawano S, Miller CW,Gombart AF et al. (1999) Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. Blood 94: 1113–1120PubMedGoogle Scholar
  364. Kerr P,Ashworth A (2001) New complexities for BRCA1 and BRCA2. Curr Biol 11: R668 - R676Google Scholar
  365. Khan J, Wei JS, Rignér M et al. (2001) Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nature Med 7: 673–679PubMedGoogle Scholar
  366. Khanna KK,Jackson SP (2001) DNA double-strand breaks: signaling, repair and the cancer connection. Nature Genet 27: 247–254Google Scholar
  367. Khosravi R, Maya R,GottliebT et al. (1999) Rapid ATM-dependent phosphorylation of MDM 2 precedes p53 accumulation in response to DNA damage. Proc Natl Acad Sci USA 96: 14973–14977PubMedGoogle Scholar
  368. Kim S, Kaminker P,Campisi J (2002) Telomeres, aging and cancer: in search of a happy ending. Oncogene 21, 503–511Google Scholar
  369. Kinzler KW,Vogelstein B (1996) Lessons from hereditary colorectal cancer. Cell 87: 159–170Google Scholar
  370. Kinzler KW, Vogelstein B (1997) Gatekeepers and caretakers. Nature 386: 761–763PubMedGoogle Scholar
  371. Kirsch DG,Kastan MB (1998)Tumor-suppressor p53: implications for tumor development and prognosis.J Clin Oncol 16:3158–3168Google Scholar
  372. Kitamura K, Hoshi S, Koike M et al. (2000) Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukemia cells with t(11;17) in combination with all-trans retinoic acid. Br J Haematol 108: 696–702PubMedGoogle Scholar
  373. Kloog Y,Cox AD (2000) RAS inhibitors:potential for cancer therapeutics. Mol Med Today 6: 398–402Google Scholar
  374. Klugbauer S, Lengfelder E, Demidchik EP et al. (1995) High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident.Oncogene 11: 2459–2467Google Scholar
  375. Klugbauer S, Pfeiffer P, Gassenhuber H et al. (2001) RET rearrangements in radiation-induced papillary thyroid carcinomas: high prevalence oftopoisomerase I sites at breakpoints and microhomology-mediated end joining in ELE1 and RET chimeric genes. Genomics 73: 149–160PubMedGoogle Scholar
  376. Knudson AG (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68: 820–823PubMedGoogle Scholar
  377. Komarov PG, Komarova EA, Kondratov RV et al. (1999) A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy.Science 285: 1733–1737Google Scholar
  378. Korsmeyer SJ (1992a) Bd-2 initiates a new category of oncogenes: regulators of cell death. Blood 80: 879–886PubMedGoogle Scholar
  379. Korsmeyer Si (1992b) Chromosomal translocations in lymphoid malignancies reveal novel proto-oncogenes. Annu Rev Immunol 10: 785–807Google Scholar
  380. Krimpenfort P, Quon KC, Mooi WJ (2001) Loss of p161NK4a confers susceptibility to metastatic melanoma in mice. Nature 413: 83–86PubMedGoogle Scholar
  381. Krontiris TG, Cooper GM (1981) Transforming activity of human tumor DNAs. Proc Natl Acad Sci USA 78: 1181–1184PubMedGoogle Scholar
  382. Kuipers J, Vaandrager JW, Weghuis DO et al. (1999) Fluorescence in situ hybridization analysis shows the frequent occurrence of 14q32.3 rearrangements with involvement of immunoglobulin switch regions in myeloma cell lines.Cancer Genet Cytogenet 109: 99–107Google Scholar
  383. Kulozik AE, Hentze MW, Hagemeier C. Bartram CR (2000) Molekulare Medi- zin.Grundlagen - Pathomechanismen - Klinik. De Gruyter, BerlinGoogle Scholar
  384. Uppers R, Dalla-Favera R (2001) Mechanisms of chromosomal translocations in B cell lymphomas.Oncogene 20: 5580–5594Google Scholar
  385. Uppers R, Klein U, Hansmann ML et al. (1999) Cellular origin of human B-cell lymphomas. N Engl J Med 341: 1520–1529Google Scholar
  386. Kwabi-Addo B,Giri D, Schmidt K et al. (2001) Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci USA 98: 11563–11568Google Scholar
  387. Laken Si, Petersen GM, Gruber SB et al. (1997) Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nature Genet 17: 79–83Google Scholar
  388. Lane DP (1984) Cell immortalization and transformation by the p53 gene. Nature 312: 596–597PubMedGoogle Scholar
  389. Lane DP (1992) p53, guardian of the genome. Nature 358:15–16Google Scholar
  390. Langerak AW,Wolvers-Tettero ILM, van Gastel-Mol EJ et al. (2001) Basic helix-loop-helix proteins E2A and HEB induce immature T-cell receptor rearrangements in nonlymphoid cells. Blood 98: 2456–2465Google Scholar
  391. Laurent E,Talpaz M, Kantarjian H et al. (2001) The BCR gene and Philadelphia chromosome-positive leukemogenesis. Cancer Res 61: 2343–2355Google Scholar
  392. Leach FS, Nicolaides NC, Papadopoulos N et al. (1993) Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75: 1215–1225PubMedGoogle Scholar
  393. Lee S-K, Yu S-L, Prakash L et al. (2002) Requirement of yeast RAD2, a homolog of human XPG gene, for efficient RNA polymerase Il transcription: implications for Cockayne syndrome.Cell 109: 823–834Google Scholar
  394. Lengauer C, Kinzler KW,Vogelstein B (1997) Genetic instability in colorectal cancers. Nature 386: 623–627Google Scholar
  395. Lengauer C, Kinzler KW,Vogelstein B (1998) Genetic instabilities in human cancers. Nature 396: 643–649Google Scholar
  396. Leon J, Kamino H, Steinberg JJ et al. (1988) H-ras activation in benign and self-regressing skin tumors (keratoacanthomas) in both humans and an animal model system. Mol Cell Biol 8: 786–793PubMedGoogle Scholar
  397. Leung SY,Yuen ST,Chung LP et al.(1999) hMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequency microsatellite instability. Cancer Res. 59:159–164Google Scholar
  398. Levens D (2002) Disentangling the MYC web. Proc Natl Acad Sci USA 99: 5757–5759PubMedGoogle Scholar
  399. Levine Al (1997) p53,the cellular gatekeeper for growth and division. Cell 88:323–331Google Scholar
  400. Levitt NC, Hickson ID (2002) Caretaker tumour suppressor genes that defend genome integrity.Trends Mol Med 8: 179–186Google Scholar
  401. Lewis SM (1994) The mechanism of V(D)J joining: lessons from molecular, immunological, and comparative analyses. Adv Immunol 56: 27–150PubMedGoogle Scholar
  402. Lewis SM, Agard E, Suh S et al. (1997) Cryptic signals and the fidelity of V(D)J joining. Mol Cell Biol 17: 3125–3136PubMedGoogle Scholar
  403. Leyland-Jones B (2002) Trastuzumab: hopes and realities. Lancet Oncol 3: 137–144PubMedGoogle Scholar
  404. Li M, Chen D, Shiloh A et al. (2002) Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 416: 648–653PubMedGoogle Scholar
  405. Li S, Ting NSY, Zheng L et al. (2000) Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response. Nature 406: 210–215PubMedGoogle Scholar
  406. Li Y, Benezra R (1996) Identification of a human mitotic checkpoint gene: hsMAD2. Science 274: 246–248PubMedGoogle Scholar
  407. Lichtenstein P, Holm NV,Verkasalo PK et al. (2000) Environmental and heri- table factors in the causation of cancer. N Engl J Med 343: 78–85PubMedGoogle Scholar
  408. Liggett WH, Sidransky D (1998) Role of the p16 tumor suppressor gene in cancer.) Clin Oncol 16: 1197–1206Google Scholar
  409. Lin SY,Makino K,Xia W etal. (2001) Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nature Cell Biol 3: 802–808Google Scholar
  410. Lin Y,Ma W, Benchimol S (2000) Pidd,a new death-domain-containing protein, is induced by p53 and promotes apoptosis. Nature Genet 26: 122–125Google Scholar
  411. Lindahl T, Wood RD (1999) Quality control by DNA repair. Science 286: 1987–1905Google Scholar
  412. Lindblom A (2001) Different mechanisms in the tumorigenesis of proximal and distal colon cancers. Curr Opin Oncol 13: 63–69PubMedGoogle Scholar
  413. Linggi B, Müller-Tidow C,van de Locht L et al.(2002)The t(8;21) fusion protein, AML1-ETO, specifically represses the transcription of the tumor suppressor in acute myeloid leukemia. Nat Med 8: 743–750Google Scholar
  414. Lingle, WL, Barrett SL, Negron VC et al. (2002) Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci USA 99: 1978–1983PubMedGoogle Scholar
  415. Lissy NA, Davis PK, Irwin M et al. (2000) A common E2F-1 and p73 pathway mediates cell death induced by TCR activation. Nature 407: 642–644PubMedGoogle Scholar
  416. Loeb LA (1991) Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 51: 3075–3075PubMedGoogle Scholar
  417. Loeb LA (2001) A mutator phenotype in cancer. Cancer Res 61: 3230–3239PubMedGoogle Scholar
  418. Lohmann DR, Brandt B,Höpping W et al. (1996)The spectrum of RB1 germline mutations in hereditary retinoblastoma. Am J Hum Genet 58: 940–949Google Scholar
  419. Lothe RA (1997) Microsatellite instability in human solid tumors. Mol Med Today 3: 61–68PubMedGoogle Scholar
  420. Louis DN, Holland EC, Cairncross JG (2001) Glioma classification:a molecular reappraisal. Am J Pathol 159: 779–786PubMedGoogle Scholar
  421. Lovett BD, Lo Nigro L, Rappaport EF et al. (2001) Near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t(4;11) translocation. Proc Natl Acad Sci USA 98: 9804–9807Google Scholar
  422. Lowenstein EJ, Daly RJ, Batzer AG et al. (1992) The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell 70: 431–442PubMedGoogle Scholar
  423. Lowy DR, Willumsen BM (1993) Function and regulation of ras. Annu Rev Biochem 62: 851–891PubMedGoogle Scholar
  424. Lundberg AS, Weinberg RA (1998) Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 18: 753–761PubMedGoogle Scholar
  425. Luo G, Santoro IM, McDaniel LD et al. (2000) Cancer predisposition caused by elevated mitotic recombination in Bloom mice. Nature Genet 26: 424–429PubMedGoogle Scholar
  426. Lynch HT, de la Chapelle A (1999) Genetic susceptibility to non-polyposis colorectal cancer.J Med Genet 36: 801–818Google Scholar
  427. Ma Y, Pannicke U, Schwarz K et al. (2002) Hairpin and overhang processing by an Artemins/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination.Cell 108: 781–794Google Scholar
  428. MacDonald TJ, Brown KM, LaFleur B et al. (2001) Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nature Genet 29: 143–152Google Scholar
  429. Macleod K (2000) Tumor suppressor genes.Curr Opin Genet Dev 10: 81–93Google Scholar
  430. MacPhee M, Chepenik KP, Liddell RA et al. (1995) The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of APCM’n-induced intestinal neoplasia.Cell81:957–966Google Scholar
  431. Madhani HD (2001) Accounting for specificity in receptor tyrosine kinase signaling. Cell 106: 9–11PubMedGoogle Scholar
  432. MageeT,Marshall C (1999) New insights into the interaction of Ras with the plasma membrane. Cell 98: 9–12Google Scholar
  433. Maher ER, Reik W (2000) Beckwith-Wiedemann syndrome: imprinting in clusters revisited.J Clin Invest 105: 247–252Google Scholar
  434. Maina F, Panté G, Helmbacher F et al. (2001) Coupling met to specific pathways results in distinct developmental outcomes. Mol Cell 7: 1293–1306PubMedGoogle Scholar
  435. Maizels N (1999) Immunoglobulin class switch recombination: will genetics provide new clues to mechanism? Am J Hum Genet 64: 1270–1275PubMedGoogle Scholar
  436. Malkin D (1994) Germline p53 mutations and heritable cancer. Annu Rev Genet 28: 443–465PubMedGoogle Scholar
  437. Malkin D, Li FP,Strong LC et al. (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 250: 1233–1238PubMedGoogle Scholar
  438. Malliri A, van der Kammen RA, Clark K et al (2002) Mice deficient in the Rac activatorTiaml are resistant to Ras-induced skin tumours. Nature 417: 867–871PubMedGoogle Scholar
  439. Maniatis T, Reed R (2002) An extensive network of coupling among gene expression machines. Nature 416: 499–506PubMedGoogle Scholar
  440. Manié S, Santoro M, Fusco A et al. (2001) The RET receptor: function in development and dysfunction in congenital malformation. Trends Genet 17: 580–589PubMedGoogle Scholar
  441. Marculescu R, Le T, Simon P et al. (2002) V(D)J-mediated translocations in lymphoid neoplasms:a functional assessment of genomic instability by cryptic sites.J Exp Med 195: 85–98Google Scholar
  442. Marin MC,Jost CA, Brooks LA et al. (2000) A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nature Genet 25: 47–54Google Scholar
  443. MarisJM,Matthay KK (1999) Molecular biology of neuroblastoma.J Clin On-col 7: 2264–2279Google Scholar
  444. Markowitz S, Wang J, Myeroff L et al. (1995) Inactivation of the Type II TGF(3 receptor in colon cancer cells with microsatellite instability. Science 268: 1336–1338PubMedGoogle Scholar
  445. Marmorstein LY, Ouchi T, Aaronson SA (1998) The BRCA2 gene product functionally interacts with p53 and RAD51. Proc Natl Acad Sci USA 95: 13869–13874PubMedGoogle Scholar
  446. Marnett LJ, Plastaras JP (2001) Endogenous DNA damage and mutation. Trends Genet 17: 214–221PubMedGoogle Scholar
  447. Marom M, Haklai R, Ben-Baruch G et al. (1995) Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid.J Biol Chem 270: 22263–22270Google Scholar
  448. Marshall CJ (1991) Tumor suppressor genes. Cell 64: 313–326PubMedGoogle Scholar
  449. Martin GM, Oshima J (2000) Lessons from human progeroid syndromes. Nature 408: 263–266PubMedGoogle Scholar
  450. Martinez LA,Naguibneva l,Lehrmann H et al. (2002) Synthetic small inhibiting RNAs: Efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci USA 99: 14849–14854Google Scholar
  451. Matolcsy A,Casali P,Warnke RA et al. (1996) Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translocated Bcl-2 gene. Blood 88: 3937–3944Google Scholar
  452. Mayo LD, Donner DB (2001) A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 98: 11598–11603PubMedGoogle Scholar
  453. McGrath J, Solter D (1984) Completion of mouse embryogenesis requires both the maternal and paternal genomes.Cell 37: 179–183Google Scholar
  454. McManus MT, Sharp PA (2002) Gene silencing in mammals by small interfering RNAs. Nature Rev Genet 3: 737–747PubMedGoogle Scholar
  455. McMurry MT, Krangel MS (2000) A role for histone acetylation in the devel- opmental regulation ofVDJ recombination. Science 287: 495–498PubMedGoogle Scholar
  456. Megonigal MD, Cheung NK, Rappaport EF et al. (2000) Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase Il inhibitors. Proc Natl Acad Sci USA 97: 2814–2819PubMedGoogle Scholar
  457. Melnick A, Licht JD (1999) Deconstructing a disease: RARa, its fusion partners, and their roles in the athogenesis of acute promyelocytic leukemia. Blood 93: 3167–3215Google Scholar
  458. Mendell JT, Dietz HC (2001) When the message goes awry:disease-producing mutations that influence mRNA content and performance. Cell 107: 411–414PubMedGoogle Scholar
  459. Menssen A, Hermeking H (2002) Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes. Proc Natl Acad Sci USA 99: 6274–6279PubMedGoogle Scholar
  460. Meyerson M (2000) Role of telomerase in normal and cancer cells.J Clin Onco1. 18: 2626–2634Google Scholar
  461. Meyn MS (1999) Ataxia-telangiectasia, cancer and the pathobiology of the ATM gene. Clin Genet 55: 289–304PubMedGoogle Scholar
  462. Michel LS, Liberal V, Chatterjee A et al. (2001) MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature 409: 355–359PubMedGoogle Scholar
  463. Michiels F, Habets GG, Stam Jet al. (1995) A role for Rac in Tiam1-induced membrane ruffling and invasion. Nature 375: 338–340PubMedGoogle Scholar
  464. MichikawaY,Mazzucchelli F,Bresolin N et al. (1999) Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication. Science 286: 774–779Google Scholar
  465. Migliazza A, Martinotti S, Chen W et al. (1995) Frequent somatic hypermutation of the 5’ noncoding region of the BCL6 gene in B-cell lymphoma. Proc Natl Acad Sci USA 92: 12520–12524PubMedGoogle Scholar
  466. Miki Y,Swensen J, Shattuck-Eidens D et aí. (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66–71Google Scholar
  467. Minn AJ, Rudin CM, Boise LH et al. (1995) Expression of bcl-xL can confer a multidrug resistance phenotype. Blood 86: 1903–1910PubMedGoogle Scholar
  468. Mitchell JR, Wood E, Collins K (1999) A telomerase component is defective in the human disease dyskeratosis congenita. Nature 402: 551–555PubMedGoogle Scholar
  469. Mitelman F, Mertens F,Johansson B (1997) A breakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nat Genet 15: 417–74Google Scholar
  470. Miyakura Y, Sugano K Konishi F et al. (2001) Extensive methylation of hMLH1 promoter region predominates in proximal colon cancer with microsatellite instability. Gastroenterology 121: 1300–1309PubMedGoogle Scholar
  471. Miyoshi Y, Nagase H, Ando H et al. (1992) Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet 1: 229–233PubMedGoogle Scholar
  472. Moodie SA, Willumsen BM, Weber MJ et al. (1993) Complexes of Ras GTP with Raf-1 and mitogen-activated protein kinase kinase. Science 260: 1658–1661PubMedGoogle Scholar
  473. Morales CP, Holt SE, Ouellette M et al. (1999) Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. Nature Genet 21: 115–117PubMedGoogle Scholar
  474. Morgan GH, Hughes T,Janssen JWG et al. (1989) Polymerase chain reaction for detection of residual leukaemia. Lancet 1: 928–929PubMedGoogle Scholar
  475. Mori Y, Sato F, Selaru FM et al. (2002) Instabilotyping reveals unique mutational spectra in microsatellite-unstable gastric cancers.Cancer Res 62: 3641–3645Google Scholar
  476. Morin PJ, Sparks AB, Korinek V et al. (1997) Activation of 13-catenin-Tcf signaling in colon cancer by mutations in 13-catenin or APC. Science 275: 1787–1790PubMedGoogle Scholar
  477. Mortuza FY, Papaioannou M, Moreira IM et al. (2002) Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia.J Clin Oncol 20: 1094–1104Google Scholar
  478. Moshous D, Callebaut I, de Chasseval R et al. (2001) Artemis, a novel DNA double-strand break repairN(D)J recombination protein,is mutated in human severe combined immune deficiency.Cell 105: 177–1786Google Scholar
  479. Moynahan ME, Pierce Ai, Jasin M (2001) BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 7: 263–272PubMedGoogle Scholar
  480. Mulligan LM, Kwok JBJ, Healey CS et al. (1993) Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363: 458–460PubMedGoogle Scholar
  481. Monger K,Werness BA, Dyson N et al. (1989) Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J 8: 4099–4105Google Scholar
  482. Muramatsu M, Kinoshita K, Fagarasan S et al. (2000) Class switch recombination and hypermutation require activation-induced cytidine deaminase ( AID), a potential RNA editing enzyme. Cell 102: 553–563Google Scholar
  483. Murray MJ, Shilo BZ, Shih C et al. (1981) Three different human tumor cell lines contain different oncogenes. Cell 25: 355–361PubMedGoogle Scholar
  484. Nakagawa H, Chadwick RB, Peltomäki P et al. (2001) Loss of imprinting of the insulin-like growth factor lI gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer. Proc Natl Acad Sci USA 98: 591–596PubMedGoogle Scholar
  485. Nakao M, Janssen JWG, Flohr T et al. (2000) Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T-cell receptor loci by LightCycler technology. Cancer Res. 60: 3281–3289PubMedGoogle Scholar
  486. Nakazawa H, English D, Randell PL et al. (1994) UV and skin cancer: specific p53 gene mutation in normal skin as a biologically relevant exposure measurement. Proc Natl Acad Sci USA 91: 360–364PubMedGoogle Scholar
  487. Nan X, Ng HH, Johnson CA et al. (1998) Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393: 386–389PubMedGoogle Scholar
  488. Nathanson KL, Wooster R, Weber BL et al. (2001) Breast cancer genetics: what we know and what we need. Nature Med 7: 552–556PubMedGoogle Scholar
  489. Nebert DW (1999) Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin Genet 56: 247–258PubMedGoogle Scholar
  490. Nekhaeva E, Bodyak ND, Kraytsberg Yet al. (2002) Clonally expanded mtDNA point mutations are abundant in individual cells of human tissues. Proc Natl Acad Sci USA 99: 5521–5526PubMedGoogle Scholar
  491. Nelson MA, Futscher BW, Kinsella T et al. (1992) Detection of mutant Ha-ras genes in chemically initiated mouse skin epidermis before the development of benign tumors. Proc Natl Acad Sci USA 89: 6398–6402PubMedGoogle Scholar
  492. Nicholls RD, Saitoh S, Horsthemke B (1998) Imprinting in Prader-Willi and Angelman syndromes.Trends Genet 14: 194–200Google Scholar
  493. Nielsen TO, West RB, Linn SC et al. (2002) Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 359: 1301–1307PubMedGoogle Scholar
  494. Nielsen, SJ, Schneider R, Bauer UM et al. (2001) Rb targets histone H3 methylation and HP1 to promoters. Nature 412: 561–565PubMedGoogle Scholar
  495. Nikolaev AY, Li M, Puskas N et al. (2003) Parc: a cytoplasmic anchor for p53. Cell 112: 29–40PubMedGoogle Scholar
  496. Nishida,T, Hirota S,Taniguchi M et al. (1998) Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nature Genet 19: 323–324Google Scholar
  497. Nissim-Rafinia M,Kerem B (2002) Splicing regulation as a potential genetic modifier.Trends Genet 18: 123–127Google Scholar
  498. Nowell PC (1976) The clonal evolution of tumor cell populations. Science 194: 23–28PubMedGoogle Scholar
  499. Nowell PC, Hungerford DA (1960) A minute chromosome in human chronic granulocytic leukemia. Science 132: 1497Google Scholar
  500. Oda E, Ohki R, Murasawa H et al. (2000e) Noxa, a BH3-only member of the Bd-2 family and candidate mediator of p53-induced apoptosis. Science 288: 1053–1058PubMedGoogle Scholar
  501. Oda K, Arakawa H,Tanaka T et al. (2000b) p53AIP1, a potential mediator of p53-dependent apoptosis,and its regulation by Ser-46-phosphorylated p53. Cell 102, 849–862Google Scholar
  502. O’Driscoll M,Cerosaletti KM,Girard PM et al. (2001) DNA ligase IV mutations identified in patients exhibiting developmental delay and immunodeficiency. Mol Cell 8: 1175–1185Google Scholar
  503. Oettinger MA, Schatz DG, Gorka C et al. (199) RAG-1 and RAG-2, adjacent genes that synergistically activate V(D)J recombination. Science 248: 1517–1523Google Scholar
  504. OlinerJD, Kinzler KW, Meltzer PS et al. (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 8083Google Scholar
  505. Paddison PJ and Hannon GJ (2002) RNA interference:the new somatic cell genetics? Cancer Cell 2: 17–23PubMedGoogle Scholar
  506. Pao GM, Janknecht R, Ruffner H et al. (2000) CBP/p300 interact with and function as transcriptional coactivators of BRCA1. Proc Natl Acad Sci USA 97: 1020–1025PubMedGoogle Scholar
  507. Papadopoulos N, Nicolaides NC, Wei YF et al. (1994) Mutation of a mutt homolog in hereditary colon cancer. Science 263: 1625–1629PubMedGoogle Scholar
  508. Papavasiliou FN, Schatz DG (2000) Cell-cycle-regulated DNA double-strand breaks in somatic hypermutation of immunoglobulin genes. Nature 408: 216–221PubMedGoogle Scholar
  509. Papavasiliou FN, Schatz DG (2002) Somatic hypermutation of immunoglobulin genes: merging mechanisms for genetic diversity. Cell 109: 535–544Google Scholar
  510. Parada LF,Tabin CJ, Shih C etal. (1982) Human EJ bladder carcinoma oncogene is a homologue of Harvey sarcoma virus ras gene. Nature 297: 474–477Google Scholar
  511. Parson R, Li GM, Longley et al. (1993) Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell 75: 1227–1236Google Scholar
  512. Pasini B, Ceccherini I, Romeo G (1996) RET mutations in human disease. Trends Genet 12: 138–144PubMedGoogle Scholar
  513. Pasqualucci L, Migliazza A, Fracchiolla N et aí. (1998) BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside 1g loci. Proc Natl Acad Sci USA 95: 11816–11821PubMedGoogle Scholar
  514. Pasqualucci L, Neumeister P, Goossens T et al. (2001) Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 412: 341–346PubMedGoogle Scholar
  515. Pawson T (1995) Protein modules and signalling networks. Nature 373: 573–580PubMedGoogle Scholar
  516. PawsonT,Scott JD (1997) Signaling through scaffold,anchoring,and adaptor proteins. Science 278: 2075–2080Google Scholar
  517. Peinado MA, Malkhosyan S, Velazquez A et al. (1992) Isolation and characterization of allelic losses and gains in colorectal tumors by arbitrarily primed polymerase chain reaction. Proc Natl Acad Sci USA 89: 10065–10069PubMedGoogle Scholar
  518. Pelengaris S, Littlewood T, Khan M et al. (1999) Reversible activation of cMyc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell 3: 565–577PubMedGoogle Scholar
  519. Pellegrini L,Yu DS, Lo T et al. (2002) Insights into DNA recombination from the structure of a RAD51–BRCA2 complex. Nature 420: 287–293Google Scholar
  520. Perou CM, Sorlie T, Eisen MB et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747–752PubMedGoogle Scholar
  521. Peters JM (2002)The anaphase-promoting complex: proteolysis in mitosis and beyond. Mol Cell 9: 931–943Google Scholar
  522. Petersen-Mahrt SK, Harris RS, Neuberger MS (2002) AID mutates E.coli suggesting a DNA deamination mechanism for antibody diversification. Nature 418: 99–103PubMedGoogle Scholar
  523. Petrij F, Giles RH, Dauwerse HG et al. (1995) Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 376: 348–351PubMedGoogle Scholar
  524. Pinkel D, Segraves R, Sudar D et al. (1998) High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nature Genet 20: 207–211PubMedGoogle Scholar
  525. Plass C, Soloway PD (2002) DNA methylation, imprinting and cancer. Eur J Hum Genet 10: 6–16PubMedGoogle Scholar
  526. Pluk H, Dorey K, Superti-Furga G et al. (2002) Autoinhibition of c-Abl. Cell 108: 247–259PubMedGoogle Scholar
  527. Polyak K, Li Y, Zhu H et al. (1998) Somatic mutations of the mitochondria) genome in human colorectal tumours. Nature Genet 20: 291–293PubMedGoogle Scholar
  528. Polyak K, Xia Y, Zweier JL et al. (1997) A model for p53-induced apoptosis. Nature 389: 300–305PubMedGoogle Scholar
  529. Pomerantz J, Schreiber-Agus N, Liégeois NJ et al. (1998) The Ink4a tumor suppressor gene product, p19ARF, interacts with MDM 2 and neutralizes MDM 2’s inhibition of p53. Cell 92: 713–723PubMedGoogle Scholar
  530. Pomeroy SL, Tamayo P, Gaasenbeek M et al. (2002) Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415: 436–442PubMedGoogle Scholar
  531. Ponder B (1988) Gene losses in human tumors. Nature 335: 400–402PubMedGoogle Scholar
  532. Ponder BA (1999) The phenotypes associated with ret mutations in the multiple endocrine neoplasia type 2 syndrome. Cancer Res 59: 1736s - 1742sPubMedGoogle Scholar
  533. Pongers-Willemse MJ, Seriu T, Stolz F et al. (1999) Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TALI deletions as PCR targets. Report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia 13: 110–118PubMedGoogle Scholar
  534. Ponzetto C, Bardelli A, Zhen Z et al. (1994) A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 77: 261–271PubMedGoogle Scholar
  535. Prescott SM, White RL (1996) Self-promotion? Intimate connections between APC and prostaglandin H synthase-2. Cell 87: 783–786PubMedGoogle Scholar
  536. Prives C (1998) Signaling to p53: breaking the MDM 2-p53 circuit. Cell 95: 5–8PubMedGoogle Scholar
  537. Quelle DE, Zindy F, Ashmun RA et al. (1995) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993–1000PubMedGoogle Scholar
  538. Quintanilla M, Brown K, Ramsden M et al. (1986) Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis.Nature 322: 78–80Google Scholar
  539. Rabbitts TH (1994) Chromosomal translocations in human cancer. Nature 372: 143–149PubMedGoogle Scholar
  540. Rahman N, Stratton MR (1998)The genetics of breast cancer susceptibility. Annu Rev Genet 32: 95–121Google Scholar
  541. Raj K, Ogston P, Beard P (2001) Virus-mediated killing of cells that lack p53 activity. Nature 412: 914–917PubMedGoogle Scholar
  542. Ramaswamy S, Ross KN, Lander ES et al. (2003) A molecular signature of metastasis in primary solid tumors. Nature Genet 33: 49–54PubMedGoogle Scholar
  543. Rampino N,Yamamoto H, IonovY et al. (1997) Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275: 967–969Google Scholar
  544. Rea S, Eisenhaber F, O’Carroll D et al. (2000) Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 406: 593–599PubMedGoogle Scholar
  545. Rebollo A, Martinez-A C (1999) Ras proteins: recent advances and new functions. Blood 94: 2971–2980Google Scholar
  546. Redner RL, Wang J, Liu JM (1999) Chromatin remodeling and leukemia: new therapeutic paradigms. Blood 94: 417–428PubMedGoogle Scholar
  547. Reich DE, Lander ES (2001) On the allelic spectrum of human disease. Trends Genet 17: 502–510PubMedGoogle Scholar
  548. Reik W, Kelsey G, Walter J (1999) Dissecting de novo methylation. Nature Genet 23: 380–382PubMedGoogle Scholar
  549. Reik W, Walter J (2001) Genomic imprinting: parental influence on the genome. Nature Genet 2: 21–32Google Scholar
  550. Reis RM, Könü-Lebleblicioglu D, Lopes JM et al. (2000) Genetic profile of gliosarcomas.Am J Pathol 156 425–432Google Scholar
  551. Reiss T (2001) Drug discovery of the future:the implications of the human genome project.Trends Biotechnol 19: 496–499Google Scholar
  552. Renan MJ (1993) How many mutations are required fortumorigenesis? Implications from human cancer data. Mol Carcinog 7: 139–146PubMedGoogle Scholar
  553. Reuter CWM, Morgan MA, Bergmann L (2000) Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood 96: 1655–1669PubMedGoogle Scholar
  554. Revy P, Muto T, Levy Y et al. (2000) Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the hyper-19M syndrome (HIGM2). Cell 102: 565–575PubMedGoogle Scholar
  555. Ribeiro RC,Sandrini F, Figueiredo B et al. (2001) An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci USA 98: 9330–9335Google Scholar
  556. Rich T, Allen RL,Wyllie AH (2000) Defying death after DNA damage. Nature 407: 777–783Google Scholar
  557. Richardson C, Jasin M (2000) Frequent chromosomal translocations induced by DNA double-strand breaks. Nature 405: 697–700PubMedGoogle Scholar
  558. Richon VM, O’Brien JP (2002) Histone deacetylase inhibitors:a new class of potential therapeutic agents for cancer treatment. Clin Cancer Res 8: 662–664PubMedGoogle Scholar
  559. Rizki A, Lundblad V (2001) Defects in mismatch repair promote telomerase-independent proliferation. Nature 411: 713–716PubMedGoogle Scholar
  560. Robert M-F, Morin S, Beaulieu N et aí. (2003) DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nature Genet 33: 61–65PubMedGoogle Scholar
  561. Robertson KD (2002) DNA methylation and chromatin–unraveling the tangled web.Oncogene 21: 5361–5379Google Scholar
  562. Robertson KD, Ait-Si-Ali S,Yokochi T et al. (2000) DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nature Genet 25: 338–342PubMedGoogle Scholar
  563. Roman-Gomez J, Castillejo JA, Jiminez A et al. (2002) 5’ CpG island hypermethylation is associated with transcriptional silencing of the p2lcipi/waft/SDI1 gene and confers poor prognosis in acute lymphoblastic leukemia. Blood 99: 2291–2296Google Scholar
  564. Romanow WJ, Langerak AW, Goebel P et al. (2000) E2A and EBF act in synergy with the V(D)J recombinase to generate a diverse immunoglobulin repertoire in nonlymphoid cells. Mol Cell 5: 343–353PubMedGoogle Scholar
  565. Rommel C,Clarke BA,Zimmermann Set al. (1999) Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 286: 1738–1741Google Scholar
  566. Rosell R, Li S, Skacel Z et al. (1993) Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene 8: 2407–2412PubMedGoogle Scholar
  567. Rosenwald A, Alizadeh AA,Widhopf G et al. (2001) Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia.J Exp Med 194: 1639–1647Google Scholar
  568. Rosenwald A, Wright G, Chan WC et al. (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346: 1937–1947PubMedGoogle Scholar
  569. Roth JA, Nguyen D, Lawrence DD et al. (1996) Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med 2: 985–991PubMedGoogle Scholar
  570. Rountree MR, Bachman KE, Baylin SB (2000) DNMT1 binds HDAC2 and a new co-repressor, DMAP1,to form a complex at replication foci. Nature Genet 25: 269–277PubMedGoogle Scholar
  571. Rowinsky EK, Windle JJ,von Hoff DD (1999) Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J Clin Onco117: 3631–3652Google Scholar
  572. Rowley JD (1973) Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243: 290–293PubMedGoogle Scholar
  573. Rowley JD, Reshmi S, Sobulo O et al. (1997) All patients with the T(11;16)(g23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Blood 90: 535–541PubMedGoogle Scholar
  574. Roy F,Therrien M (2002) MAP kinase module:the Ksr connection. Curr Biol 12: R325 - R327Google Scholar
  575. Roz L, Wu CL, Porter S et aí. (1996) Allelic imbalances on chromosome 3p in oral dysplastic lesions:an early event in oral carcinogenesis.Cancer Res 56: 1228–1231Google Scholar
  576. Rudolph KL, Chang S, Lee HW et al. (1999) Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 96: 701–712PubMedGoogle Scholar
  577. Ruffner H, Joazeiro CAP, Hemmati D et al. (2001) Cancer-predisposing mutations within the RING domain of BRCA1:loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc Natl Acad Sci USA 98: 5134–5139PubMedGoogle Scholar
  578. Ruggero D, Grisendi S, Piazza F et al. Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science 299: 259–262Google Scholar
  579. RüschoffJ,Wallinger S, Dietmaier W et al. (1998) Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection. Proc Natl Acad Sci USA 95: 11301–11306Google Scholar
  580. Ruttledge MH,Sarrazin J,Rangaratnam S et aí. (1994) Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nature Genet 6: 180–184Google Scholar
  581. Saha S, Bardelli A, Buckhaults P et al. (2001) A phosphatase associated with metastasis of colorectal cancer. Science 294: 13431346Google Scholar
  582. Samuels-Lev Y, O’Connor DJ, Bergamaschi D et al. (2001) ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 8: 781–794PubMedGoogle Scholar
  583. Sandig V, Brand K, Herwig S et al. (1997) Adenovirally transferred pi 61NK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nature Med 3: 313–319PubMedGoogle Scholar
  584. Sassone-Corsi P, Mizzen CA,Cheung Pet al. (1999) Requirement of Rsk-2 for epidermal growth factor-activated phosphorylation of histone H3. Science 285: 886–891Google Scholar
  585. Sattler M, Salgia R (1997) Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL. Cytokine Growth Factor Rev 8: 63–79PubMedGoogle Scholar
  586. Savage DG, Antman KH (2002) Imatinib mesylate–a new oral targeted therapy. N Engl J Med 346: 683–693PubMedGoogle Scholar
  587. Savitsky K, Bar-Shira A, Gilad S et al. (1995) A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268: 1749–1753PubMedGoogle Scholar
  588. Sawyers CL (2002) Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell 1: 413–415PubMedGoogle Scholar
  589. Scheffner M,Werness BA,Huibregtse JM et al. (1990)The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129–1136Google Scholar
  590. Scheijen B, Griffin JD (2002) Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease. Oncogene 21: 3314–3333PubMedGoogle Scholar
  591. Schindler T, Bornmann W, Pellicena Petal. (2000) Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase.Science 289: 1938–1942Google Scholar
  592. Schmidt L, Duh FM,Chen F et aí. (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nature Genet 16: 68–73Google Scholar
  593. Schnittger S, Schoch C, Dugas M et aí.(2002) Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal disease. Blood 100: 59–66Google Scholar
  594. Schnitzer G, Sif S, Kingston RE et al. (1998) Human SWI/SNF interconverts a nucleosome between its base state and a stable remodeled state.Cell 94: 17–27Google Scholar
  595. Schreiber SL, Bernstein BE (2002) Signaling network model of chromatin. Cell 1 1 1: 771–778Google Scholar
  596. Schröck E,du Manoir S,Veldman T et aí. (1996) Multicolor spectral karyotyping of human chromosomes. Science 273: 494–497Google Scholar
  597. Schwab M, Alitalo K, Klempnauer KH et al. (1983) Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 305: 245–248PubMedGoogle Scholar
  598. Schwarz K, Gauss GH,Ludwig L etal. (1996) RAG mutations in human B cell-negative SCID.Science 274: 97–99Google Scholar
  599. Sciacco M, Bonilla E, Schon EA et al. (1994) Distribution of wild-type and common deletion forms of mtDNA in normal and respiration-deficient muscle fibers from patients with mitochondrial myopathy. Hum Mol Genet 3: 13–19PubMedGoogle Scholar
  600. Sebolt-Leopold JS, Dudley DT, Herrera R et al. (1999) Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nature Med 5: 810–816PubMedGoogle Scholar
  601. Seeger RC, Brodeur GM, Sather H et al. (1985) Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313: 1111–1116PubMedGoogle Scholar
  602. Sellers WR, Kaelin WG (1997) Role of the retinoblastoma protein in the pathogenesis of human cancer.J Clin Oncol 15: 3301–3312Google Scholar
  603. Sévenet N, Lellouch-Tubiana A, Schofield D et al. (1999) Spectrum of hSNF5/IN11 somatic mutations in human cancer and genotype-phenotype correlations. Hum Mol Genet 8: 2359–2368PubMedGoogle Scholar
  604. Shade) GS, Clayton DA (1997) Mitochondria) DNA maintenance in vertebrates.Annu Rev Biochem 66: 409–435Google Scholar
  605. Shapiro G, Harper JW (1999) Anticancer drug targets:cell cycle and checkpoint control.) Clin Invest 104: 1645–1653Google Scholar
  606. Sharpless NE, Bardeesy N, Lee KH et al. (2001) Loss of pi 6INK4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 413: 8694Google Scholar
  607. Sharpless NE, Ferguson DO, O’Hagan RC et al. (2001) Impaired nonhomologous end-joining provokes soft tissue sarcomas harboring chromosomal translocations, amplifications, and deletions. Mol Cell 8: 1187–1196PubMedGoogle Scholar
  608. Shaulian E, Karin M (2002) AP-1 as a regulator of cell life and death. Nature Cell Biol 4: E131 - E136PubMedGoogle Scholar
  609. Shay JW, Wright WE (2002) Telomerase: A target for cancer therapeutics. Cancer Cell 2: 257–265Google Scholar
  610. Shay JW, Zou Y, Hiyama E et al. (2001) Telomerase and cancer. Hum Mol Genet 10: 677–685PubMedGoogle Scholar
  611. Shen JC, Loeb LA (2000) The Werner syndrome gene: the molecular basis of RecQ helicase-deficiency diseases.Trends Genet 16: 213–220Google Scholar
  612. Sherr CJ (1996) Cancer cell cycles. Science 274: 1672–1677PubMedGoogle Scholar
  613. Sherr CJ, Weber JD (2000) The ARF/p53 pathway. Curr Opin Genet Dev 10: 94–99PubMedGoogle Scholar
  614. Shi B,Yaremko B, Hajian G et al (2000) The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo. Cancer Chemother Pharmacol 46: 387–93Google Scholar
  615. Shih IM,Zhou W, Goodman SN et al. (2001) Evidence that genetic instability occurs at an early stage of colorectal tumorigenesis.Cancer Res 61: 818–822Google Scholar
  616. Shipp MA, Ross KN,Tamayo Petal. (200) Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nature Med 8: 68–74Google Scholar
  617. Side L, Taylor B, Cayouette M (1997) Homozygous inactivation of the NFI gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N Engl J Med 336: 1713–1717PubMedGoogle Scholar
  618. Sidransky D (1997) Nucleic acid-based methods for the detection of cancer. Science 278: 1054–1058PubMedGoogle Scholar
  619. Sidransky D (2002) Emerging molecular markers of cancer. Nature 2: 210–219Google Scholar
  620. Sidransky D,Tokino T, Hamilton SR et al. (1992) Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 256: 102–105Google Scholar
  621. Singal R, Ginder GD (1999) DNA methylation. Blood 93: 4059–4070PubMedGoogle Scholar
  622. Singh KK, Russell J,Sigala B et al. (1999) Mitochondrial DNA determines the cellular response to cancer therapeutic agents. Oncogene 18: 6641–6646PubMedGoogle Scholar
  623. Siu LL, Chan JK, Wong KF et al. (2002) Specific patterns of gene methylatin in natural killer cell lymphomas: p73 is consistently involved. Am J Pathol 160: 59–66PubMedGoogle Scholar
  624. Skorski T (2002) Oncogenic tyrosine kinases and the DNA-damage response. Nature Rev Cancer 2: 351–360Google Scholar
  625. Slamon DJ, Clark GM, Wong SG et a. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182PubMedGoogle Scholar
  626. Slamon DJ, Leyland-Jones B, Shak S et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792PubMedGoogle Scholar
  627. Slebos RJC, Kibbelaar RE, Dalesio O et al.(1990) K-RAS oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323: 561–565Google Scholar
  628. Smith G, Carey FA, Beattie J et al. (2002) Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci USA 99: 9433–9438PubMedGoogle Scholar
  629. Soares J, Pinto AE, Cunha CV et al. (1999) Global DNA hypomethylation in breast carcinoma:correlation with prognostic factors and tumor progression. Cancer 85: 112–118PubMedGoogle Scholar
  630. Soengas MS, Alaron RM, Yoshida H et al. (1999) Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science 284: 156158Google Scholar
  631. Soengas MS, Capodieci P, Polsky D et al. (2001) Inactivation of the apopto- sis effector Apaf-1 in malignant melanoma. Nature 409: 207–211PubMedGoogle Scholar
  632. Solé F, Espinet B,Sanz GF et al. (2000) Incidence,characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. BrJ Haematol 108: 346–356Google Scholar
  633. Solinas-Toldo S,Lampel S,Stilgenbauer Set aí. (1997) Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances. Genes Chromosomes Cancer 20: 399–407Google Scholar
  634. Songyang Z, Carraway Ill KL, Eck MJ et al. (1995) Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature 373: 536–539PubMedGoogle Scholar
  635. Soong R, Grieu F, Robbins P (1997) p53 alterations are associated with improved prognosis in distal colonic carcinomas. Clin Cancer Res 3: 1405–1411Google Scholar
  636. Soussi T (1996) The p53 tumour suppressor gene: a model for molecular epidemiology of human cancer. Mol Med Today 1: 32–37Google Scholar
  637. Souza RF, Appel R,Yin J et al. (1996) Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumours. Nature Genet 14: 255–257PubMedGoogle Scholar
  638. Speicher MR, Ballard SG, Ward DC (1996) Karyotyping human chromosomes by combinatorial multi-fluor FISH. Nature Genet 12: 368–375PubMedGoogle Scholar
  639. Spotswood HT, Turner BM (2002) An increasingly complex code.J Clin Invest 110: 577–582Google Scholar
  640. Spruck CH, Won KA, Reed SI (1999) Deregulated cyclin E induces chromosome instability. Nature 40: 297–300Google Scholar
  641. StankovicT,Weber P,Stewart G et aí. (1999) Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet 353: 26–29Google Scholar
  642. Stansel RM, de Lange T, Griffith JD (2001) T-Ioop assembly in vitro involves binding of TRF2 near the 3’ telomeric overhang. EMBO J 20: 5532–5540PubMedGoogle Scholar
  643. Stark GR, Wahl GM (1984) Gene amplification. Ann Rev Biochem 53: 447–491PubMedGoogle Scholar
  644. Staunton JE, Slonim DK,Coller HA et al. (2001) Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci USA 98: 10787–10792PubMedGoogle Scholar
  645. Stavropoulos DJ, Bradshaw PS, Li X et al. (2002) The Bloom syndrome helicase BLM interacts with TRF2 in ALT cells and promotes telomeric DNA synthesis. Hum Mol Genet 11: 3135–3144PubMedGoogle Scholar
  646. Steenman M, Westerveld A, Mannens M (2000) Genetics of Beckwith-Wiedemann syndrome-associated tumors: common genetic pathways. Genes Chromosomes Cancer 28: 1–13PubMedGoogle Scholar
  647. Steenman MJC, Rainier S, Dobry CJ et al. (1994) Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms’tumour. Nature Genet 7: 433–439PubMedGoogle Scholar
  648. Stehelin D,Varmus HE, Bishop JM et al. (1976) DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature 260: 170–173Google Scholar
  649. Steinbach G, Lynch PM, Phillips RK et al. (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342: 1946–1952PubMedGoogle Scholar
  650. Stewart GS, Maser RS, Stankovic T et al. (1999) The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxiatelangiectasia-like disorder. Cell 99: 577–587PubMedGoogle Scholar
  651. Stiewe T, Pützer BM (2000) Role of the p53-homologue p73 in E2F1-induced apoptosis. Nature Genet 26: 464–469PubMedGoogle Scholar
  652. Stilgenbauer S, Leupolt E, Ohl S et al. (1995) Heterogeneity of deletions involving RB-1 and the D13525 locus in B-cell chronic lymphocytic leukemia revealed by fluorescence in situ hybridization.Cancer Res 55: 3475–3477Google Scholar
  653. Stilgenbauer S, Schaffner C, Litterst A et al. (1997) Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nature Med 3: 1155–1159PubMedGoogle Scholar
  654. Stoler DL, Chen N, Basik M et al (1999)The onset and extent of genomic instability in sporadic colorectal tumor progression. Proc Natl Acad Sci USA 96: 15121–15126Google Scholar
  655. Storz G (2002) An expanding universe of noncoding RNAs. Science 296: 1260–1263PubMedGoogle Scholar
  656. Strahl BD, Allis CD (2000) The language of covalent histone modifications. Nature 403: 41–45PubMedGoogle Scholar
  657. Struewing JP, Hartge P,Wacholder Set al. (1997) The risk of cancer associated with specific mutations of BRCA1 abd BRCA2 among Ashkenazi Jews. N Engl J Med 336: 1401–1408PubMedGoogle Scholar
  658. Su LK, Kinzler KW, Vogelstein B et al. (1992) Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene.Science 256: 668–670Google Scholar
  659. Su ZZ, Lebedeva IV, Gopalkrishnan RV et al. (2001) A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells. Proc Natl Acad Sci USA 98: 10332–10337PubMedGoogle Scholar
  660. Sukumar S, Notario V, Martin -Zanca D et al. (1983) Induction of mammary carcinomas in rats by nitroso-methylurea involves malignant activation of H-ras-1 locus by single point mutations. Nature 306: 658–661PubMedGoogle Scholar
  661. Surani MA, Barton SC, Norris ML (1984) Development of reconstituted mouse eggs suggests imprinting of the genome during gametogenesis. Nature 308: 548–550PubMedGoogle Scholar
  662. Sutherland GR, Richards RJ (1995)The molecular basis of fragile sites in human chromosomes.CurrOpin Genet Dev 5:323–327Google Scholar
  663. Suzuki H, Gabrielson E, Chen W (2002) A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nature Genet 31: 141–149PubMedGoogle Scholar
  664. Svejstrup JQ (2002) Mechanisms of transcription-coupled DNA repair. Nature Rev Mol Cell Biol 3: 21–29Google Scholar
  665. Talpaz M, Silver RT, Druker BJ et al. (2002) Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99: 1928–1937PubMedGoogle Scholar
  666. Tamura G, Yin J, Wang Set al. (2000) E-cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst 92: 569–573PubMedGoogle Scholar
  667. Tanaka H, Arakawa H,Yamaguchi T et al. (2000) A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404: 42–49PubMedGoogle Scholar
  668. T’Ang A,VarleyJM,Chakraborty S et al. (1988) Structural rearrangement of the retinoblastoma gene in human breast carcinoma. Science 242: 263–266Google Scholar
  669. Taniguchi T, D’Andrea AD (2002) Molecular pathogenesis of Fanconi anemia.lnt J Hematol 75: 123–128Google Scholar
  670. Taniguchi T, Gacia-Higuera I, Xu B et al. (2002) Convergence of the Fanconi anemia and ataxia telangiectasia signaling pathways. Cell 109: 459–472PubMedGoogle Scholar
  671. Tao W, Levine Ai (1999) P1 9ARF stabilizes p53 by blocking nucleo-cytoplas- mic shuttling of Mdm2. Proc Natl Acad Sci USA 96: 6937–6941PubMedGoogle Scholar
  672. Taub R, Kirsch I, Morton C et al. (1982) Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci USA 79: 7837–7841PubMedGoogle Scholar
  673. Taub JW, Konrad MA, Ge Y et al. (2002) High frequency of leukemic clones in newborn screening blood samples of children with B-precursor acute lymphoblastic leukemia. Blood 99: 2992–2996PubMedGoogle Scholar
  674. Taylor JK,Zhang QQ,Wyatt JR et al. (1999) Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nature Biotechnol 17: 1097–1100Google Scholar
  675. Teitz T, Wei T, Valentine MB et al. (2000) Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nature Med 6: 529–535PubMedGoogle Scholar
  676. Tetsu O, McCormick F (1999) ß-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422–426PubMedGoogle Scholar
  677. Thangavelu M, Olopade O, Beckman E et al. (1990) Clinical, morphologic, and cytogenetic characteristics of patients with lymphoid malignancies characterized by both t(14;18)(q32;q21) and t(8;14)(q24;q32) or t(8;22)(g24;g11).Genes Chromosomes Cancer 2: 147–158Google Scholar
  678. The C. elegans Sequencing Consortium (1998) Genome sequence of the nematode C elegans: a platform for investigating biology. Science 282: 2012–2018Google Scholar
  679. The CHEK2-Breast Cancer Consortium (2002) Low-penetrance susceptibility to breast cancer due to CHEK2*1100deIC in noncarriers of BRCA1 or BRCA2 mutations. Nature Genet 31: 55–59Google Scholar
  680. Therrien JP, Drouin R, Baril C et al. (1999) Human cells compromised for p53 function exhibit defective global and transcription-coupled nucleotide excision repair, whereas cells compromised for pRb function are defective only in global repair. Proc Natl Acad Sci USA 96: 15038–15043PubMedGoogle Scholar
  681. Thiede C, Steudel C, Mohr B et al. (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99: 4326–4335PubMedGoogle Scholar
  682. Thorlacius S,Struewing JP, Hartge Petal. (1998) Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 352: 1337–1339Google Scholar
  683. Tomlinson I, Sasieni P, Bodmer W (2002) How many mutations in cancer? Am J Pathol 160: 755–758PubMedGoogle Scholar
  684. Toyota M,Ahuja N, Ohe-Toyota M et al. (1999) CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci USA 96: 8681–8686Google Scholar
  685. Toyota M, Kopecky J,Toyota MO et al. (2001) Methylation profiling in acute myeloid leukemia. Blood 97: 2823–2829PubMedGoogle Scholar
  686. Trivier E, De Cesare D, Jacquot Set al. (1996) Mutations in the kinase Rsk-2 associated with Coffin-Lowry syndrome. Nature 384: 567–570PubMedGoogle Scholar
  687. Tsujii M,Kawano S,Tsujii Set aí. (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93: 705–716Google Scholar
  688. Turner BM (2002) Cellular memory and the histone code.Cell 111:285–291 Tuschl T (2002) Expanding small RNA interference. Nature Biotechnol 20: 446–448Google Scholar
  689. Tutt A, Ashworth A (2002) The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med 8: 571–576PubMedGoogle Scholar
  690. Tycko B (2000) Epigenetic gene silencing in cancer. J Clin Invest 105: 401–407PubMedGoogle Scholar
  691. Ullrich A, Schlessinger J (1990) Signal transduction by receptors with tyrosine kinase activity.Cell 61: 203–212Google Scholar
  692. Urano T, Emkey R, Feig LA (1996) Ral-GTPases mediate a distinct downstream signaling pathway from Ras that facilitates cellular transformation. EMBO J 15: 810–816PubMedGoogle Scholar
  693. Vafa O,Wade M, Kern S et al.(2002) c-Myc can induce DNA damage,increase reactive oxygen species, and mitigate p53 function:a mechanism for oncogene-induced genetic instability. Mol Cell 9: 1031–1044Google Scholar
  694. van derVelden PA,Sandkuijl LA,Bergman Wet aí. (2001) Melanocortin-1 receptor variant R151 C modifies melanoma risk in Dutch families with melanoma. Am J Hum Genet 69: 774–779Google Scholar
  695. van de Vijver MJ, He YD, van’t Veer U (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999–2009PubMedGoogle Scholar
  696. van Dongen JJM, Wolvers-Tettero ILM (1991a) Analysis of immunoglobulin and T cell receptor genes. Part I: basic and technical aspects.Clin Chim Acta 198: 1–91Google Scholar
  697. van Dongen JIM, Wolvers-Tettero ILM (1991b) Analysis of immunoglobulin and T cell receptor genes. Part II: possibilities and limitations in the diagnosis and management of lymphoproliferative diseases and related disorders. Clin Chim Acta 198: 93–174PubMedGoogle Scholar
  698. van Dongen JJM, Seriu T, Panzer-Grümayer ER et al. (1998) Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 352: 1731–1738PubMedGoogle Scholar
  699. van Gool Ai, van der Horst GTJ, Citterio E et al. (1 997) Cockayne syndrome: defective repair of transcription? EMBO J 16: 4155–4162Google Scholar
  700. van’t Veer LJ, Dai H,van de Vijver MJ et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530–536Google Scholar
  701. Vanasse GJ,Concannon P,Willerford (1999) Regulated genomic instability and neoplasia in the lymphoid lineage. Blood 94: 3997–4010Google Scholar
  702. Varley H, Pickett HA, Foxon JL et al. (2002) Molecular characterization of inter-telomere and intra-telomere mutations in human ALTcells.Nature Genet 30: 301–305Google Scholar
  703. Varon R, Vissinga C, Platzer M et al. (1998) Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome.Cell 93: 467–476Google Scholar
  704. Vaziri H, Dessain SK, Eaton EN et al. (2001) hSIR2S1RT1 functions as an NAD-dependent p53 deacetylase. Cell 107: 149–159Google Scholar
  705. Venkitaraman AR (2002) Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108: 171–182PubMedGoogle Scholar
  706. Venter JC, Adams MD, Myers EW et al. (2001) The sequence of the human genome. Science 291: 1304–1351PubMedGoogle Scholar
  707. Versteege 1, Sévenet N, Lange J et al. (1998) Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394: 203–206Google Scholar
  708. Vetter IR,Wittinghofer A (2001) The guanine nucleotide-binding switch in three dimensions. Science 294: 1299–1304Google Scholar
  709. Virtaneva K, Wright FA,Tanner SM et al. (2001) Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics.Proc Natl Acad Sci USA 98: 1124–1129Google Scholar
  710. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase-akt pathway in human cancer. Nature Rev Cancer 2: 489–501Google Scholar
  711. Vogelstein B, Kinzler KW (1992) p53 function and dysfunction. Cell 70: 523–526Google Scholar
  712. Vogelstein B, Fearon ER, Hamilton SR et al. (1988) Genetic alterations during colorectal tumor development. N Engl J Med 319: 525–532PubMedGoogle Scholar
  713. Vogelstein B, Fearon ER, Kern SE et al. (1989) Allelotype of colorectal carcinomas. Science 244: 207–211PubMedGoogle Scholar
  714. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408: 307–310PubMedGoogle Scholar
  715. von Bubnoff N, Schneller F, Peschel C et al. (2002) BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571:a prospective study. Lancet 359: 487–491Google Scholar
  716. Vousden KH (2000) p53:death star.Cell 103:691–694Vousden KH, Lu X (2002) Live or let die:The cell’s response to p53. Nature Rev Cancer 2:594–604Google Scholar
  717. Vulliamy T, Marrone A, Goldman F et al. (2001) The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature 413: 432–435PubMedGoogle Scholar
  718. Wadayama B,Toguchida J, Shimizu et al. (1994) Mutation spectrum of the retinoblastoma gene in osteosarcomas.Cancer Res 54: 3042–3048Google Scholar
  719. Walker JR, Corpina RA, Goldberg J (2001) Structure of the Ku heterodimer bound to DNA and its implications for double-strand break repair.Natu re 412: 607–614Google Scholar
  720. Wallace DC (1999) Mitochondria) diseases in man and mouse. Science 283: 1482–1488PubMedGoogle Scholar
  721. Walton KM, Dixon JE (1993) Protein tyrosine phosphatases. Annu Rev Biochem 62: 101–120PubMedGoogle Scholar
  722. Wang XW,Tseng A, Ellis NA et al. (2001) Functional interaction of p53 and BLM DNA helicase in apoptosis.J Biol Chem 276: 32948–32955Google Scholar
  723. Wang Y, Cortez D,Yazdin P et al. (2000) BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures.Genes Dev 14: 927–939Google Scholar
  724. WebbT, Latif F (2001) Rett syndrome and the MECP2 gene.J Med Genet 38: 217–223Google Scholar
  725. Weber JDTaylor LJ,Roussel MF et al. (1999) Nucleolar Arf sequesters Mdm2 and activates p53. Nature Cell Biol 1: 20–25Google Scholar
  726. Weber RG,Boström J,Wolter M et al. (1997) Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci USA 94: 14719–14724Google Scholar
  727. Weinstein JN, Myers TG,O’Connor PM et aí. (1997) An information-intensive approach to the molecular pharmacology of cancer. Science 275: 343–349Google Scholar
  728. Weiss A, Schlessinger J (1998) Switching signals on or off by receptor d imerization. Cel l 94: 277–280Google Scholar
  729. Weiss WA, Aldape K, Mohapatra G et al. (1997) Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 16: 2985–2995PubMedGoogle Scholar
  730. Weissman BE, Saxon PJ, Pasquale SR et al. (1987) Introduction of a normal human chromosome 11 into a Wilms’ tumor cell line controls its tumorigenic expression. Science 236: 175–180PubMedGoogle Scholar
  731. Wessendorf S, Fritz B, Wrobel G et al. (2002) Automated screening for genomic imbalances using matrix-based comparative genomic hybridization. Lab Invest 82: 47–60PubMedGoogle Scholar
  732. Wiemels JL, Cazzaniga G, Daniotti M et al. (1999) Prenatal origin of acute lymphoblastic leukaemia in children. Lancet 354: 1499–1503PubMedGoogle Scholar
  733. Wiemels IL, Greaves M (1999) Structure and possible mechanisms of TELAML1 gene fusions in childhood acute lymphoblastic leukemia. Cancer Res 59: 4075–4082PubMedGoogle Scholar
  734. Wilks AF (1993) Protein tyrosine kinase growth factor receptors and their ligands in development,differentiation,and cancer.Adv Cancer Res 60: 43–73Google Scholar
  735. Williams CS, Smalley W, DuBois RN (1997) Aspirin use and potential mechanisms for colorectal cancer prevention.J Clin Invest 100: 1–5Google Scholar
  736. Willis TG, Dyer MJS (2000) The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood 96: 808–822PubMedGoogle Scholar
  737. Wilson DM, Thompson LH (1997) Life without DNA repair. Proc Natl Acad Sci USA 94: 12754–12757PubMedGoogle Scholar
  738. Wilson JF, Weale ME, Smith AC et al. (2001) Population genetic structure of variable drug response. Nature Genet 29: 265–269PubMedGoogle Scholar
  739. Windle B, Draper BW, Yin YX et al. (1991) A central role for chromosome breakage in gene amplification, deletion formation, and amplicon integration. Genes Dev 5: 160–174PubMedGoogle Scholar
  740. Wolf U (1995) The genetic contribution to the phenotype. Hum Genet 95: 127–148PubMedGoogle Scholar
  741. Wolf U (1997) Identical mutations and phenotypic variation. Hum Genet 100: 305–321PubMedGoogle Scholar
  742. Wong IHN, Ng MHL, Huang DP et aí. (2000) Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. Blood 95: 1942–1949PubMedGoogle Scholar
  743. Wood RD, Mitchell M, Sgouros J et I. (2001) Human DNA repair genes. Science 291: 1284–1289PubMedGoogle Scholar
  744. Wooster R (2000) Cancer classification with DNA microarrays is less more? Trends Genet 16: 327–329PubMedGoogle Scholar
  745. Wooster R, Bignele G, Lancaster J et al. (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378: 789–792PubMedGoogle Scholar
  746. Wu K-J, Grandori C,Amacker M et al. (1999) Direct activation ofTERT transcription by c-MYC. Nature Genet. 21: 220–224PubMedGoogle Scholar
  747. Wu X, Pandolfi PP (2001) Mouse models for multistepp tumorigenesis. Trends Cell Biol 11: 52–59Google Scholar
  748. Xu B, Kim ST, Kastan MB (2001) Involvement of Brca1 in S-phase and G2-phase checkpoints after ionizing irradiation. Mol Cell Biol 21: 3445–3450PubMedGoogle Scholar
  749. Xu GF, O’Connell P,Viskochil D et al. (1990) The neurofibromatosis type 1 gene encodes a protein related to GAP.Cell 63: 835–841Google Scholar
  750. Yamanishi Y, Boyle DL, Rosengren S et al. (2002) Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc Natl Acad Sci USA 99: 10025–10030PubMedGoogle Scholar
  751. Yan H, Dobbie Z, Gruber SB (2002) Small changes in expression affect predisposition to tumorigenesis. Nature Genet 30: 25–26PubMedGoogle Scholar
  752. Yan SP, Chen C-M, Shi H et al. (2001) Dissecting complex epigenetic alterations in breast cancer using CpG island microarrays. Cancer Res 61: 8375–8380PubMedGoogle Scholar
  753. Yanagisawa A, Ohtake K,Ohashi K et al. (1993) Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation.Cancer Res 53: 953–956Google Scholar
  754. Yang A, McKeon F (2000) p63 and p73: p53 mimics, menaces and more. Nature Rev Mol Cell Biol 1: 199–207Google Scholar
  755. Yang E, Korsmeyer SJ (1996) Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 88: 386–401PubMedGoogle Scholar
  756. YanoT, Sander CA,Clark HM et al. (1993) Clustered mutations in the second exon of the MYC gene in sporadic Burkitt’s lymphoma. Oncogene 8: 2741–2748Google Scholar
  757. Yarden RJ,Brody LC (1999) BRCA1 interacts with components of the histone deacetylase complex. Proc Natl Acad Sci USA 96: 4983–4988Google Scholar
  758. Yin Y,Tainsky MA, Bischoff FZ et al. (1992) Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cel 170: 937–948Google Scholar
  759. Yoshiura K, Kanai Y, Ochiai A et al. (1995) Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci USA 92: 7416–7419PubMedGoogle Scholar
  760. You M, Candrian U, Maronpot RR et al. (1989) Activation of the Ki-ras protooncogene in spontaneously occurring and chemically induced lung tumors of the strain A mouse. Proc Natl Acad Sci USA 86: 3070–3074PubMedGoogle Scholar
  761. Young RA (2000) Biomedical discovery with DNA arrays. Cell 102: 9–15PubMedGoogle Scholar
  762. Yu CE, Oshima J, Fu YW et al. (1996) Positional cloning of the Werner’s syndrome gene. Science 272: 258–262PubMedGoogle Scholar
  763. Yu J, Hu S, Wang J et al. (2002) A draft sequence of the rice genome (Oryza sativa L. ssp. indica ). Science 296: 79–92Google Scholar
  764. Yu J, Zhang L, Hwang PM et al. (1999) Identification and classification of p53-regulated genes. Proc Natl Acad Sci USA 96: 14517–14522PubMedGoogle Scholar
  765. Yu J, Zhang L, Hwang PM et al. (2001a) PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 7: 673–682PubMedGoogle Scholar
  766. Yu Q, Geng Y, Sicinski P (2001 b) Specific protection against breast cancers by cyclin D1 ablation. Nature 411: 1017–1021Google Scholar
  767. Zacchi P,Gostissa M, Uchida T et al. (2002) The prolyl isomerase Pin 1 reveals a mechanism to control p53 functions after genotoxic insults. Nature 419: 853–857Google Scholar
  768. Zang KD, Singer H (1967) Chromosomal constitution of meningiomas. Nature 216: 84–85PubMedGoogle Scholar
  769. Zhang Y, Mukhopadhyay T, Donehower LA et al. (1993) Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Hum Gene Ther4: 451–460Google Scholar
  770. Zhang Y, Reinberg D (2001) Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails.Genes Dev 15: 2343–2360Google Scholar
  771. Zhang Y, Xiong Y,Yarbrough WG (1998) ARF promotes MDM 2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725–734Google Scholar
  772. Zhang Z,Wang Y,Vikis HG et al. (2001) Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nature Genet 29: 25–33Google Scholar
  773. Zhao S, Weng, YC, Yuan SSF et al. (2000) Functional link between ataxia telangiectasia and Nijmegen breakage syndrome gene products. Nature 405: 473–477PubMedGoogle Scholar
  774. Zheng L, Li S, Boyer TG et al. (2000) Lessons learned from BRCA1 and BRCA2.Oncogene 19: 6159–6175Google Scholar
  775. Zheng H,You H,Zhou XZ et al. (2002) The prolyl isomerase Pinl is a regulator of p53 in genotoxic response. Nature 419: 849–853Google Scholar
  776. Zhong Q, Chen CF, Li Set al. (1999) Association of BRCA1 with the hRad50hMre11-p95 complex and the DNA damage response. Science 285: 747–750PubMedGoogle Scholar
  777. Zhou BBS, Elledge SJ (2000) The DNA damage response: putting checkpoints in perspective. Nature 408: 433–439PubMedGoogle Scholar
  778. Zhou ZQ, Hurlin PJ (2001) The interplay between Mad and Myc in proliferation and differentiation.Trends Cell Biol 11: S10 - S14Google Scholar
  779. Zhu XD, Küster B, Mann M et al. (2000) Cell-cycle-regulated association of RAD50/MRE11/NBS1 with TRF2 and human telomeres. Nature Genet 25: 347–351PubMedGoogle Scholar
  780. Zuber J,Tchernitsa Di, Hinzmann Bet al. (2000) A genome-wide survey of RAS transformation targets. Nature Genet 24: 144–152Google Scholar
  781. Zwick E, Bange J, Ullrich A (2002) Receptor tyrosine kinases as targets for anticancer drugs.Trends Mol Med 8: 17–23Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • C. R. Bartram

There are no affiliations available

Personalised recommendations